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Molecular recognition, particularly as it applies to strong binding interactions
between complementary ligand/receptor molecules in solution, is important in such
varied areas as molecular biology, pharmacology, synthetic chemistry, and chemical
detection. Strong binding is the additive result of a number of specific, weak, noncovalent interactions occurring between complementary molecules. This dissertation
reports on the energetics of forming complexes between small molecules and model
DNA constructs. Ligands included cationic and metallated cationic porphyrins and
polyheterocyclic ruthenium compounds. DNA receptors included double stranded BDNAs (hairpin and short linear sequences) as well G-quadruplex DNAs. Thermodynamic
data were collected using isothermal titration calorimetry, circular dichroism
spectropolarimetry, ultraviolet-visible spectroscopy, and mass spectrometry. The
measured thermodynamic parameters included the changes in free energy, enthalpy and
entropy for ligand/receptor complex formation as well as the stoichiometry of the stable
complexes. The first section of this dissertation reports that the binding of cationic
porphyrins to model G-quadruplex DNA may proceed through two pathways, end

stacking and intercalation. Modulating the number of pyridinium groups on a pyridinium
substituted porphyrin yielded differing binding thermodynamics leading to the
understanding that a balance of surface area, charge, and geometry affect the ability of a
porphyrin to bind to G-quadruplex DNA. Further investigations into the binding of
metallated porphyrins developed the understanding that the geometry of the central metal
ion affected not only the thermodynamics but could also inhibit the intercalative mode. It
was previously shown that the high affinity binding for binuclear polyheterocyclic
ruthenium compounds proceeds through an intercalative mode. To further understand the
binding process and the structure-function relationship of the ligand components, the
binding of smaller mononuclear complexes that were representative of portions of the
binuclear complex was examined in this dissertation. While limiting the intercalative
ability lowered the binding affinity, the mononuclear complex with the full intercalating
bridge was able bind to DNA with a higher affinity than the binuclear complex. These
studies have been successful in part in determining the contributions of numerous weak
interactions including: charge (Coulombic interactions), H-bonding, hydrophobic
interactions, and solvent structure (solvation changes), to the overall energetics of this
molecular recognition process. The first section of this dissertation reports that the
binding of cationic porphyrins to model G-quadruplex DNA may proceed through two
pathways, end stacking and intercalation. Modulating the number of pyridinium groups
on a pyridinium substituted porphyrin yielded differing binding thermodynamics leading
to the understanding that a balance of surface area, charge, and geometry affect the ability
of a porphyrin to bind to G-quadruplex DNA. Further investigations into the binding of
metallated porphyrins developed the understanding that the geometry of the central metal

ion affected not only the thermodynamics but could also inhibit the intercalative mode. It
was previously shown that the high affinity binding for binuclear polyheterocyclic
ruthenium compounds proceeds through intercalation. To further understand the binding
process and the structure-function relationship of the ligand components, the binding of
smaller mononuclear complexes that were representative of portions of the binuclear
complex was examined in this dissertation. While limiting the intercalative ability
lowered the binding affinity, the mononuclear complex with the full intercalating bridge
was able bind to DNA with a higher affinity than the binuclear complex. These studies
have been successful in part in determining the contributions of numerous weak
interactions including: charge (Coulombic interactions), H-bonding, hydrophobic
interactions, and solvent structure (solvation changes), to the overall energetics of this
molecular recognition process.

DEDICATION
This dissertation is dedicated to my wife, Joy DuPont, and to my mother, Linda
DuPont. Joy has been a constant support throughout my dissertation studies, even when I
woke her up with 3 a.m. alarms to set up ITC experiments. Her selfless care of our
daughter, Eleanor, allowed me to put in the extra time needed to finish my dissertation
work.
Linda emphasized the importance of education and has been a source of
encouragement and support throughout my studies. Her strength and persistence taught
me to always push forward and strive for the best.

ii

ACKNOWLEDGEMENTS
I would like to thank Dr. Gerald B. Rowland for his support and guidance during
the initial phase of my graduate work. I would also like to thank Dr. Edwin A. Lewis for
advising me during the remainder of my graduate studies and supporting my interest in
drug binding in addition to organic chemistry. They both provided ample advice and
encouragement when my research hit inevitable roadblocks.
I would also like to thank the professors on my committee, Drs. Emerson, Fitzkee,
Mead, and Sygula, for the time they have spent advising my path and the reviews of my
research they have performed. Dr. Emerson also helped a great deal throughout my
studies and offered insightful thoughts during my metallated porphyrin research.
I owe a great deal of gratitude to Drs. Vu Le and Kate Henderson, who both
guided me into the biophysical realm when I transitioned from organic synthesis. I
would also like to thank Clinton Mikek for his help in the process and for becoming a
great friend, even though I am faster on the draw with a pipette.

iii

TABLE OF CONTENTS
DEDICATION ........................................................................................................ ii
ACKNOWLEDGEMENTS ................................................................................... iii
LIST OF TABLES ................................................................................................ vii
LIST OF FIGURES ............................................................................................. viii
LIST OF SCHEMES............................................................................................ xiii
CHAPTER
I.

INTRODUCTION .................................................................................................1
1.1
1.2
1.3

Background................................................................................................1
Introduction to deoxyribonucleic acid (DNA) ..........................................1
B DNA .......................................................................................................6
1.3.1 Alkylating agents .................................................................................7
1.3.2 Minor groove binding agents...............................................................7
1.3.3 B-DNA intercalative agents ..............................................................10
1.4
G-quadruplex DNA .................................................................................12
1.4.1 Quadruplex conformations and structural stability ...........................14
1.4.2 Quadruplex binding ligands ..............................................................15
1.4.3 The implications of the interactions of G-quadruplex binding
ligands with G-rich oncogenes ..........................................................18
1.4.3.1 c-MYC NHE-III1 G-quadruplex studies ......................................18
1.4.3.2 BCL-2 G-quadruplex studies .......................................................21
Outline of this work .................................................................................22
1.5
1.6
References ...............................................................................................25
II.

THE EFFECT OF PYRIDYL SUBSTITUENTS ON TH
ETHERMODYNAMICS OF PORPHYRIN BINDING TO GQUADRUPLEX DNA ........................................................................................31
2.1
2.2
2.3

Abstract....................................................................................................31
Introduction .............................................................................................32
Materials and Methods ............................................................................34
2.3.1 Binding studies ..................................................................................34
2.3.2 Porphyrin ligand synthesis ................................................................36
iv

2.4
2.5
2.6
III.

CALORIMETRIC AND SPECTROSCOPIC INVESTIGATIONS OF
THE BINDING OF METALLATED PORPHYRINS TO GQUADRUPLEX DNA ........................................................................................62
3.1
3.2
3.3
3.4
3.5
3.6

IV.

2.3.2.1 Dipyrromethane 1 (30): ...............................................................39
2.3.2.2 1-formyl dipyrromethane 2 (26): .................................................39
2.3.2.3 5-(4-pyridyl) dipyrromethane 4 (29): ..........................................40
2.3.2.4 1,9-Diformyl-5-(4-pyridyl)dipyrromethane 5 (26):.....................40
2.3.2.5 (5,5’-(pyridine-4-ylmethylene)bis(1H-Pyrrole-5,2diyl)dimethanol 6 (26): ...............................................................41
2.3.2.6 4-Pyridylporphyrin 7 (26): ..........................................................41
2.3.2.7 S-2-Pyridyl isonicotinothioate 8 (31,32): ....................................41
2.3.2.8 1-Isonicotinoyl-5-(4-pyridyl) dipyrromethane 9 (31,32): ...........42
2.3.2.9 5,10-Di(4-pyridyl)porphyrin 10 (32): ..........................................43
2.3.2.10 5,15-Di-(4-pyridyl)porphyrin 12 (26): ..................................43
2.3.2.11 5, 10, 15-Tri-4-pyridylporphyrin 13 (26): .............................44
2.3.2.12 General procedure for the quaternization of porphyrin
pyridyl groups with iodomethane (26): .......................................45
2.3.2.12.1 5-(N-methylpyridynium-4-yl) porphyrin P(5): ..............45
2.3.2.12.2 5,10-Di(N-methylpyridinium-4-yl) porphyrin
P(5,10): ..................................................................................45
2.3.2.12.3 5,15-Di(N-methylpyridinium-4-yl)porphyrin
P(5,15): ..................................................................................45
2.3.2.12.4 5,10,15-tri(N-methyl pyridinium-4-yl)porphyrin
P(5,10,15): .............................................................................46
Results .....................................................................................................46
Discussion................................................................................................53
References ...............................................................................................58

Abstract....................................................................................................62
Introduction .............................................................................................63
Materials and methods .............................................................................65
Results .....................................................................................................67
Discussion................................................................................................74
References ...............................................................................................84

THE THERMODYNAMIC EFFECTS OF LIGAND STRUCTURE ON
THE MOLECULAR RECOGNITION OF RUTHENIUM
COMPLEXES WITH B-DNA ...........................................................................87
4.1
4.2
4.3
4.4
4.5
4.6

Abstract....................................................................................................87
Introduction .............................................................................................88
Material and methods ..............................................................................90
Results .....................................................................................................92
Discussion................................................................................................99
Conclusion .............................................................................................103
v

4.7

References .............................................................................................104

APPENDIX
A.

SUPPLEMENTARY INFORMATION FOR CHAPTER III ...........................107
A.1
A.2
A.3

B.

Complete ITC titration profiles .............................................................108
Titrations at 60 mM supporting electrolyte ...........................................127
Circular dichroism spectra for titrations ................................................130

SUPPLEMENTARY INFORMATION FOR CHAPTER IV ...........................133
B.1
B.2

ITC final figures ....................................................................................134
Circular dichroism spectra for titrations ................................................146

vi

LIST OF TABLES
2.1

A Comparison of the thermodynamic parameters for binding the
porphyrin ligands P(5), P(5,10), P(5,15), P(5,10,15) and TMPyP4 to
G-quadruplex DNA. .......................................................................................53

3.1

Thermodynamic parameters obtained from ITC experiments for the
formation of the apo-TMPyP4 complexes with hTel22 in Na+ and K+
buffer conditions. ............................................................................................73

3.2

Thermodynamic parameters obtained from ITC experiments for the
formation of metallated-TMPyP4 complexes with hTel22 Gquadruplex in 150 mM Na+ buffer conditions. ...............................................74

4.1

Thermodynamic data obtained from ITC experiments performed at
298 K for the interaction between ligands and dsDNA in Na+ BPES
buffer ..............................................................................................................94

B.1

Thermodynamic Data obtained from ITC Experiments performed at
298 K for the interactions between ligands and 25bp duplex in tris
buffer. ...........................................................................................................149

vii

LIST OF FIGURES
1.1

Stick structures of double helical DNA conformation. ....................................3

1.2

Model of the replication of DNA. Image created by Mariana Ruiz and
is released to the public domain. ......................................................................4

1.3

Model of the transcription of DNA into messenger RNA (mRNA). ...............5

1.4

Diagram of the Watson-Crick base pairing of thymine with adenine
and cytosine with guanine ................................................................................6

1.5

Crystal structure of the binding of cisplatin to DNA through the N7
position of adjacent guanines (1,2-intrastrand linkage). ..................................8

1.6

A) Structure of Thiazotropsin B. B) Cartoon of the solution structure
for the 2:1 complex of Thiazotropsin B with d(CGACGCGTCG)2. B)
was reproduced with permission from Alniss et al. (2)..................................10

1.7

Chemical structure of doxorubicin. ................................................................11

1.8

Crystal structure of the binding mode of doxorubicin with duplex
DNA. ..............................................................................................................12

1.9

A) Chemical diagram of a G-tetrad. B) Simplistic cartoon of a Gquadruplex. .....................................................................................................14

1.10

Diagram of the conformational heterogeneity possible with Gquadruplex structures. Reproduced from Phan et al. with permission
(43). ................................................................................................................16

1.11

Chemical structures for the G-quadruplex interacting compounds: A)
Telomestatin B) TMPyP4 C) Diseleno sapphyrin (Se2SAP) D) Braco19. ...................................................................................................................18

1.12

Cartoon diagram showing the route of c-MYC transcription silencing
by G-quadruplex stabilizing compounds. Reproduced from Brooks et
al. with permission (54). .................................................................................20

1.13

A) Chemical structure of TMPyP2. B) Chemical structure of
TMPyP3. C) Chemical structure of TMPyP4.................................................22
viii

2.1

CD spectra of WT 27-mer Bcl-2 G-quadruplex in the absence and
presence of the P(5,10,15) ligand. ..................................................................47

2.2

CD spectra are shown for the Bcl-2 G-quadruplex and its 2:1
complexes with P(5,15), P(5,10,15) and TMPyP4........................................48

2.3

Electrospray ionization mass spectra for WT 27-mer Bcl-2 Gquadruplex and its complexes with P(5), P(5,10), P(5,15), and
P(5,15,20). ......................................................................................................49

2.4

Panel A shows the thermogram for the addition of the 115 μM WT27mer Bcl-2 titrant into 5 μM P(5,15), Panel B shows the
thermogram for heat of dilution of the porphyrin solution, that is, the
addition of buffer into 5 μM P(5,15), and Panel C shows the corrected
enthalpogram for titration DNA into porphyrin ligand along with the
model fit (▬) and best fit parameters for formation of the 2:1
complex. .........................................................................................................52

3.1

Electrospray ionization mass spectra for solutions containing hTel22
G-quadruplex DNA and excess amounts Co-TMPyP4 (panel A), NiTMPyP4 (panel B), Cu-TMPyP4 (panel C), and Zn-TMPyP4 (panel
D). ...................................................................................................................69

3.2

CD titration data for complexation of the hTel22 G-quadruplex with
apo- and metallated-TMPyP4 in 150 mM Na+ BPES buffer. ........................70

3.3

CD titration data for complexation of the hTel22 G-quadruplex with
apo and metallated-TMPyP4 in 150 mM K+ BPES buffer.............................71

3.4

Typical nonlinear regression fits for the titration of apo (○)
andmetallated-TMPyP4 into hTel22 G-quadruplex in 150 mM K+
BPES buffer. ...................................................................................................73

4.1

Structures of the Ru2+ compounds used in this study. ....................................90

4.2

CD spectra for the subsequent titrations of Ru2+ complexes into DNA
in tris buffer. ...................................................................................................96

4.3

Minimized models of MP (A), Rp2d (B), and Rp3 (C) interacting
with duplex DNA; calculated by Clinton G. Mikek of the Lewis lab. ...........97

4.4

ESI-MS of free hairpin DNA and hairpin DNA incubated with a
slight excess of the indicated ligand. DNA illustrated in 4B was
prepared with DNA shown in 4A, while 4D, 4E, and 4F were
prepared with DNA shown in 4C. ..................................................................98

ix

A.1

Representative ITC titration profile for the titration of apo-TMPyP4
into hTel22 in 150 mM K+ BPES buffer. .....................................................108

A.2

Representative ITC titration profile for the titration of Cu-TMPyP4
into hTel22 in 150 mM K+ BPES buffer. .....................................................109

A.3

Representative ITC titration profile for the titration of Ni-TMPyP4
into hTel22 in 150 mM K+ BPES buffer. .....................................................110

A.4

Representative ITC titration profile for the titration of Co-TMPyP4
into hTel22 in 150 mM K+ BPES buffer. .....................................................111

A.5

Representative ITC titration profile for the titration of Zn-TMPyP4
into hTel22 in 150 mM K+ BPES buffer. .....................................................112

A.6

Representative titration profile for the dilution of apo-TMPyP4 in 150
mM K+ BPES buffer. Note the low endothermic heats of dilution
seen. ..............................................................................................................113

A.7

Representative titration profile for the dilution of Cu-TMPyP4 in 150
mM K+ BPES buffer. ....................................................................................114

A.8

Representative titration profile for the dilution of Ni-TMPyP4 in 150
mM K+ BPES buffer. Note the low endothermic heats of dilution
seen. ..............................................................................................................115

A.9

Representative titration profile for the dilution of Co-TMPyP4 in 150
mM K+ BPES buffer. Note the low endothermic heats of dilution
seen. ..............................................................................................................116

A.10

Representative titration profile for the dilution of Zn-TMPyP4 in 150
mM K+ BPES buffer. Note the low endothermic heats of dilution seen ......117

A.11

Representative ITC titration profile for the titration of apo-TMPyP4
into hTel22 in 150 mM Na+ BPES buffer. ..................................................118

A.12

Representative ITC titration profile for the titration of Cu-TMPyP4
into hTel22 in 150 mM Na+ BPES buffer. ...................................................119

A.13

Representative ITC titration profile for the titration of Ni-TMPyP4
into hTel22 in 150 mM Na+ BPES buffer. ...................................................120

A.14

Representative ITC titration profile for the titration of Co-TMPyP4
into hTel22 in 150 mM Na+ BPES buffer. ...................................................121

A.15

Representative ITC titration profile for the titration of Zn-TMPyP4
into hTel22 and in 150 mM Na+ BPES buffer. ............................................122
x

A.16

Representative ITC titration profile for the dilution of apo-TMPyP4 in
150 mM Na+ BPES buffer. ...........................................................................123

A.17

Representative titration profile for the dilution of Cu-TMPyP4 in 150
mM Na+ BPES buffer. ..................................................................................124

A.18

Representative titration profile for the dilution of Ni-TMPyP4 in 150
mM Na+ BPES buffer. ..................................................................................125

A.19

Representative titration profile for the dilution of Zn-TMPyP4 in 150
mM Na+ BPES buffer. ..................................................................................126

A.20

Representative ITC titration enthalpogram for the titration of apoTMPyP4 into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer. .................127

A.21

Representative ITC titration enthalpogram for the titration of NiTMPyP4 into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer. .................128

A.22

Representative ITC titration enthalpogram for the titration of CuTMPyP4 into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer ..................129

A.23

CD spectra for the titration of TMPyP4 into hTel22 in either 60 or
150 mM Na+ or K+ BPES. ............................................................................130

A.24

CD spectra for the titration of Ni-TMPyP4 into hTel22 in either 60 or
150 mM Na+ or K+ BPES. ............................................................................131

A.25

CD spectra for the titration of Cu-TMPyP4 into hTel22 in either 60 or
150 mM Na+ or K+ BPES. ............................................................................132

B.1

Representative ITC titration profile for the titration of MP into tris
buffer. ...........................................................................................................134

B.2

Representative ITC titration profile for the titration of MP into 25 bp
duplex DNA in tris buffer.............................................................................135

B.3

Representative ITC titration profile for the titration of Rp2d into tris
buffer. ...........................................................................................................136

B.4

Representative ITC titration profile for the titration of Rp2d into 25
bp duplex DNA in tris buffer........................................................................137

B.5

Representative ITC titration profile for the titration of Rp3 into tris
buffer. ...........................................................................................................138

B.6

Representative ITC titration profile for the titration of Rp3 into 25 bp
duplex DNA in tris buffer.............................................................................139
xi

B.7

Representative ITC titration profile for the titration of MP into Na+
BPES buffer. .................................................................................................140

B.8

Representative ITC titration profile for the titration of MP into 25 bp
duplex DNA in Na+ BPES buffer. ................................................................141

B.9

Representative ITC titration profile for the titration of Rp2d into Na+
BPES buffer. .................................................................................................142

B.10

Representative ITC titration profile for the titration of Rp2d into 25
bp duplex DNA in Na+ BPES buffer. ...........................................................143

B.11

Representative ITC titration profile for the titration of Rp3 into Na+
BPES buffer. .................................................................................................144

B.12

Representative ITC titration profile for the titration of RP3 into 25 bp
duplex DNA in Na+ BPES buffer. ................................................................145

B.13

CD spectra for the titration of MP into duplex DNA in Na+ BPES
buffer. ...........................................................................................................146

B.14

CD spectra for the titration of Rp2d into duplex DNA in Na+BPES
buffer. ...........................................................................................................147

B.15

CD spectra for the titration of Rp3 into duplex DNA in Na+BPES
buffer. ...........................................................................................................148

xii

LIST OF SCHEMES
2.1

Synthetic routes for the four cationic porphyrin ligands used in this
study ...............................................................................................................38

xiii

CHAPTER I
INTRODUCTION
1.1

Background
Cancer is the second most prevalent cause of death in the United States (1). The

cellular basis for cancer, malignancy, occurs when damage to a cell’s deoxyribonucleic
acid (DNA) is greater than cellular repair ability. Primary views on the “hallmarks of
cancer” established the following characteristics: sustaining proliferative signaling,
enabling replicative immortality, inducing angiogenesis (formation of new blood vessels
for the transport of nutrients), evading growth suppressors, resisting cell death, and
activating invasion and metastasis (the spread of cancer from one location to another, e.g.
liver to lung) (2). Recent “emerging hallmarks” have been added to the list: deregulating
cellular energetics, avoiding immune destruction, genome instability and mutation, and
tumor-promoting inflammation (3). While the emerging hallmarks have similarities to
and basis in the seminal hallmarks, both groups offer insight into possible treatment
mechanisms. As cancer is often caused by mutations within the genome, DNA offers an
attractive target for therapies (4, 5).
1.2

Introduction to deoxyribonucleic acid (DNA)
DNA is possibly the most important aspect of an organism. This

biomacromolecule codes for everything that an organism is or will become. The
principal structure of DNA within a cell is that of its tertiary, double helical structure of
1

antiparallel strands as discovered by Watson and Crick (6). Hydrogen bonding between
complementary purine and pyrimidine bases stabilizes this double helical structure (6, 7).
The hydrogen bonding can primarily be seen between the purines adenine and guanine
with the pyrimidines thymine and cytosine respectively. Three main types of DNA exist:
A, B, and Z-form DNA (Figure 1.1). Of the three the most prevalent form of DNA, BDNA, is most often used as a therapeutic target (8). Other, noncanonical intermolecular
and intramolecular DNA structures are believed to exist in vivo including G-quadruplex,
I-motif, triplex, hairpin, and cruciform DNA structures (9-11).
DNA has two primary responsibilities: replication, the semiconservative process
by which two molecules of daughter DNA are formed from the parent DNA, as
illustrated in Figure 1.2, and transcription, the process by which the DNA’s coding is
copied by messenger RNA (mRNA) to be translated into specific amino acid sequences
to code for proteins, as illustrated in Figure 1.3 (9). Errors in either process may be
phenotypically silent or may have dire consequences for the function of the organism and
cause disease (3, 4). The binding of molecules to DNA is of intense interest in
understanding the formation of diseases, as well as how to treat them (12). The sequence
of the nucleotides that make up DNA allows distinct functional environments that
influence the binding of other molecules to DNA, including environments that allow
intercalation, negatively charged binding areas for cations, and grooves that allow for the
burying of hydrophobic molecules away from water (5, 12, 13).

2

Figure 1.1

Stick structures of double helical DNA conformation.

Reproduced with permission from Wood, B. R., The importance of hydration and DNA
conformation in interpreting spectra of cells and tissues. Chemical Society Reviews 2016
45 (7) 1980-1998.
A) Stick diagram of A-DNA B) Stick diagram of B-DNA C) Stick diagram of Z-DNA.
A-DNA is characterized by a widened minor groove relative to B-DNA and exhibits a
complete turn every 11 base pairs, with base pairs being angled roughly 20 degrees from
the axis perpendicular to the helical axis. The base pairs are separated with a distance of
2.55 Å. B-DNA exhibits a smaller minor groove and a larger major groove with 10.5
base pairs comprising a complete turn and a diameter of 20 Å. Distances between BDNA base pairs are 3.4 Å. While A- and B-DNA are right handed, Z-DNA is
characterized by a left handed double helical conformation with bases extending beyond
the core of the helix and the presence of only one groove. One complete turn of Z-DNA
comprises 12 base pairs with a 3.7 Å rise between base pairs and a helical diameter of 18
Å.

3

Figure 1.2

Model of the replication of DNA. Image created by Mariana Ruiz and is
released to the public domain.

Topoisomerase causes a transient nicking of the DNA backbone to release the supercoil
causing helical tension that occurs during replication. Helicase separates the lagging and
leading strands as it propels itself forward along the strand. Single-strand DNA-binding
(SSB) proteins bind to the single-stranded DNA directly behind the helicase, preventing
the duplex from reforming. The SSB proteins bind without interfering with subsequent
protein interactions. DNA polymerase polymerizes nucleotides in the 5’ to 3’ direction,
using free mononucleotides as substrates for the leading strand, by addition of the 5’ end
of the nucleotide phosphate to the 3’-OH end of the deoxyribose. DNA primase
introduces an RNA based primer on the lagging strand. DNA polymerase is then able to
create Okazaki fragments in a 5’ to 3’ direction. Exonuclease, not pictured, removes the
RNA primer. Additional Okazaki fragments are then formed further upstream. The 5’
end of the former fragment is then joined with the 3’-OH of the newer fragment by DNA
ligase. Through this semiconservative process, two new daughter strands are formed
from the single parent template strand (9).

4

Figure 1.3

Model of the transcription of DNA into messenger RNA (mRNA).

Reused from Clancy, S., DNA transcription. Nature Education 2008, 1 (1:41) with
permission (14).
A) Transcription factors bind to promoter regions upstream of the target DNA. RNA
polymerase then binds at the initiation site of the template strand. B) RNA polymerase
forms a transcription bubble by cleaving the hydrogen bonds which bind the two strands
to each other. RNA polymerase proceeds down the DNA template strand in a 3’ to 5’
manner, matching ribonucleotides to the template strand and forming an RNA transcript
strand in a 5’ to 3’ manner which matches the coding DNA strand complementary to the
template strand. C) mRNA elongation ends when the polymerase extends to the
termination site and the mRNA is separated from the template strand (14)

5

1.3

B DNA
DNA has several distinct conformations within the nucleus. However, for the bulk

of therapies, double helical B-DNA provides several distinct possibilities as a target (1517). Major grooves (22 Å wide) and minor grooves (12 Å wide) found in the phosphate
backbone of DNA offer binding specificity, a feature that is exploited in DNA-protein
binding (18). This specificity arises not only from steric constraints, but also from
hydrogen bond acceptor and donor positioning among other intermolecular interactions,
including π-stacking, halogen bonding, and cation-π interactions. The specific thymineadenine and cytosine-guanine binding offers distinct differences in binding environments,
as shown in Figure 1.4 (19).

Figure 1.4

Diagram of the Watson-Crick base pairing of thymine with adenine and
cytosine with guanine

Distinct functional environments are present in the major and minor grooves. The major
groove displays a hydrogen bond acceptor at the O4 of thymine, donor at adenine N6 and
acceptor at adenine N7. The minor groove exhibits a hydrogen bond acceptor at thymine
O2 and adenine N3. This positioning of hydrogen bond acceptors and donors allows for
some of the sequence specificity seen in DNA minor groove binding molecules

6

1.3.1

Alkylating agents
The first group of DNA targeting therapies in the modern era consisted of

nitrogen mustards (12). These covalently modify DNA, offering inhibition of DNA
processes and ultimately leading to cellular death. Their primary mechanism of action is
alkylation of the N7 of guanine (5). This nitrogen is nucleophilic and able to react with
the electron deficient carbon(s) of the mustard (5, 12). Further “generations” of
alkylating/covalently modifying agents have involved transition metals, e.g. platinum in
Cisplatin, a frontline cancer treatment. Cisplatin causes 1,2-intrastrand d(GpG) linkages
through covalent modification of the N7 of guanine as the primary product, as shown in
Figure 1.5 (20). The drawback of the majority of alkylating agents is their nonspecificity
in targeting. Because of this, patients experience a myriad of side effects and even refuse
treatment due to the negative effects of the drugs (21).
1.3.2

Minor groove binding agents
Advances in therapies have arisen through drugs that have sequence specificities

or act solely on DNA (platins, mustards, and other alkylating agents are non-specific to
DNA and are able to alkylate proteins and other intracellular and extracellular molecules)
(5). Further research has evolved into numerous accounts of minor groove binding
agents dependent on non-covalent interactions (5, 12, 19, 22-24). A large majority of
these agents exhibit a characteristic “crescent shape” believed to enhance their ability to
lie within the minor groove of DNA (5). In addition to the crescent shape, most minor
groove binders are characterized by the presence hydrogen bond donors and acceptors, in
addition to some amount of positive charge. The positive charge allows for favorable
ionic interactions with the negative phosphate backbone (5, 12).
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Figure 1.5

Crystal structure of the binding of cisplatin to DNA through the N7
position of adjacent guanines (1,2-intrastrand linkage).

Adapted with permission from Todd et al. (20).

Brostallicin, a polyamide, crescent shaped minor groove specific alkylating agent,
shows specificity to 5’-AAAG-3’ and alkylates the N3 of adenine. Brostallicin has an
appreciable therapeutic index with an ED50 of 0.6-2 nM (as low as 0.46 nM in a cell line
known for a high level of glutathione, a reducing agent commonly seen in hypoxic
tumors). The binding affinity of Brostallicin for the minor groove of B-DNA arises from
the hydrogen bond donating and accepting ability of secondary amides (hydrogen bond
8

donation from the amide proton and hydrogen bond accepting ability through a lone pair
on the amide carbonyl oxygen) (15). Numerous studies have been performed on
distamycin and related pyrrole polyamide crescent shaped minor grove binders that do
not covalently modify DNA as Brostallicin does (5, 12, 19, 24, 25)
Thiazotropsin B, shown in Figure 1.6a is one such polyamide minor groovebinding drug. The polyamide skeleton gives crescent shape conformational ability as well
as hydrogen bond acceptors and donors (16). Thiazotropsin B stabilizes dACGCGT to a
greater extent than dACTAGT. Substitution of a pyrrole with imidazole and
transformation of the aldehyde to a methyl ketone yields Thiazotropsin A, which has the
reverse affinity for the two nucleotides (16, 19). This yields additional credence to the
role of functional groups in base pair specificity. Additionally, Thiazotropsin B binding
to DNA has a stoichiometry of 2:1 and binds in a “head to tail” directionality, as shown
in Figure 1.6b. This is due to functional group association compatibility within the dimer
formed from two Thiazotropsin B units. This binding mode increases the width of the
minor groove. This binding driven widening of the minor groove compacts the major
groove and offers allosteric inhibition of the binding of DNA binding proteins to the
DNA major groove in this sequence, offering the potential of chemotherapeutic ability
for this class of molecules (19).
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Figure 1.6

A) Structure of Thiazotropsin B. B) Cartoon of the solution structure for
the 2:1 complex of Thiazotropsin B with d(CGACGCGTCG)2. B) was
reproduced with permission from Alniss et al. (2).

The two Thiazotropsin B ligands are self-associated as a dimer in a head to tail manner
within the minor groove of the duplex. The presence of the ligand dimer causes
substantial distortion of the duplex through widening of the minor groove and subsequent
compaction and deepening of the major groove, which would allow for allosteric
inhibition of protein binding to the major groove (2).
1.3.3

B-DNA intercalative agents
In addition to minor groove electrostatic interactions, molecules are able to

intercalate between base pairs in several types of DNA, including B-form duplex DNA.
The intercalation of molecules is due mostly to favorable π-π interactions. A planar,
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conjugated molecule is able to insert into base pairs and exhibit π-orbital overlap with the
planar, conjugated base pairs (12, 22).
Doxorubicin (Figure 1.7), another frontline drug, acts through this intercalative
mode by selectively intercalating between cytosine and guanine, as shown in Figure 1.8
(22, 26). It also offers additional stabilization through hydrogen bonding from its amino
sugar group to flanking base pairs, bonding to a cytosine deoxyribose and a thymine
carbonyl. Binding to d(CGATCG) is tighter than that of d(CGTACG), where the thymine
and adenine have been swapped. This specificity is believed to be due to the presence of
the amino-sugar, and crystal structures support this hypothesis (22). Subtle differences in
DNA configuration and ligand functional groups can have drastic changes in the binding
ability of ligands; however, a major downfall to doxorubicin therapy is cardiomyopathy,
which may arise due to the oxidative stress caused by the incomplete specificity in the
action of doxorubicin (27, 28).

Figure 1.7

Chemical structure of doxorubicin.
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Figure 1.8

Crystal structure of the binding mode of doxorubicin with duplex DNA.

Adapted with permission from Frederick, C. A.; Williams, L. D.; Ughetto, G.; Van der
Marel, G. A.; Van Boom, J. H.; Rich, A.; Wang, A. H. J., Structural comparison of
anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29
(10), 2538-2549. 1990. American Chemical Society.
Association proceeds through intercalation between cytosine and guanine residues with
additional stabilization from hydrogen bonding between the doxorubicin amino sugar and
cytosine and thymine heteroatom.
1.4

G-quadruplex DNA
The G-quadruplex is a non-canonical four stranded DNA construct capable of

forming from DNA sequences with high frequencies of guanine. G-quadruplexes offer
an attractive therapeutic target as there are roughly 3.7 million guanine rich sequences
within the human genome. These sequences occur in numerous areas including the cMYC, BCL-2, KRAS, c-KIT, and VEGF oncogene promoter regions as well as the 3’
overhang of DNA, the telomere (29).
The first report of guanine-guanine based associations was published by Ivar
Bang in 1910 in which it was reported that millimolar concentrations of guanylic acid
formed a gel (30). Further investigations demonstrated that self-assembly of guanylic
12

acids into tetrameric units able to form a helical structure was responsible for the gel-like
properties (31). The link between guanylic acid gels and the formation of G-quadruplex
structures from DNA was not made until Henderson et al. observed that guanine rich
telomeric sequence oligonucleotides exhibited abnormally high stability under denaturing
conditions (32). Since then, numerous investigations have shown through the use of Gquadruplex specific binding antibodies, as well as spectroscopic investigations, have
shown that G-quadruplexes are able to form in vitro and are likely able to form in vivo,
and are therefore a physiologically relevant target in drug therapies (29, 33-37).
G-quadruplexes are formed through non-Watson-Crick guanine-guanine based
association. Hoogsteen hydrogen bonding among four separate guanine residues can form
a square planar structure, a G-tetrad, shown in figure 1.9a (38). These tetrads are then
able to self-assemble and stack through π-π stacking to form a G-quadruplex depending
on the number of contiguous guanines within a sequence, as shown in Figure 1.9b.
Monovalent cations present in the channel formed among the bases of the G-quadruplex
offer additional stabilization and are often, at least in biologically relevant systems,
sodium or potassium ions (39).
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Figure 1.9

A) Chemical diagram of a G-tetrad. B) Simplistic cartoon of a Gquadruplex.

Hoogsteen hydrogen bonding among four guanine residues forms a square planar Gtetrad. G-tetrads are then able to form a G-quadruplex through π-π stacking. The
presence of a monovalent metal ion in the central channel offers additional stabilization
(39).
1.4.1

Quadruplex conformations and structural stability
G-quadruplex DNA is able to adapt a number of sequence orientations including

parallel, antiparallel, and mixed conformations, as illustrated in figure 1.10 (38).
Intramolecular and intermolecular G-quadruplexes can be formed, including
unimolecular, bimolecular and tetramolecular structures. In general, G-quadruplexes
formed in potassium solutions tend to favor a parallel conformation while Gquadruplexes formed in sodium solutions tend to form antiparallel G-quadruplexes, but
14

this is by no means the rule (40-42). The polymorphism of G-quadruplex structures in
evident in that fact that in addition to the general trends, parallel G-quadruplexes may be
seen in sodium solutions with antiparallel G-quadruplexes present in potassium solution.
Structural stability also varies as it is dependent upon not only the presence and
identity of the cation present within the channel, but also on the number of nucleotides on
both the 5’ and 3’ side of the structure as well as the number and composition of the
nucleotides forming the loops within the complex. Higher concentrations of the
supporting electrolyte help to stabilize the structure to a greater extent than lower
concentrations. Dettler et al. reported that the first and second melting temperature for a
24 nucleotide long oligonucleotide c-MYC WT 24 mer (5’TGGGGAGGGTGGGGAGGGTGGGGA-3’) were 71.0 °C and 80.1 °C respectively in
30 mM K+ and 78.8 °C and 93.1 °C respectively in 130 mM K+ (44). Conversely, Blume
et al. and other groups have reported that the presence of divalent cations causes a
decrease in structural stability, even in the presence of potassium ions (45, 46).
1.4.2

Quadruplex binding ligands
G-quadruplexes may also be stabilized or destabilized by the presence of one or

more bound small molecules that generally exhibit some type of conjugated or aromatic,
planar core that is able to non-covalently bind to the G-quadruplex through π-π stacking.
In addition to the conjugated or aromatic, planar core, a number of G-quadruplex binding
small molecules also exhibit some degrees of cationic charge that is able to offer
additional binding stability through ionic interactions with the negatively charged
phosphate backbone of the G-quadruplex (47).
15

Figure 1.10

Diagram of the conformational heterogeneity possible with G-quadruplex
structures. Reproduced from Phan et al. with permission (43).

The red lines in the figures represent the loops, cyan squares are syn- guanine residues
and magenta colored squares are anti- oriented guanine residues. A) Figure for the
conformation of residues 2 through 22 for d[AGGG(TTAGGG)3] (hTel22) in Na+
solution. B) Figure for the conformation of residues 2 through 22 for htel22 in K+ crystal.
C) Figure for the conformation of residues 3 through 23 for d[TAGGG(TTAGGG)3] in K
solution. D) Figure for the conformation of residues 3 through 23 for
d[TAGGG(TTAGGG)3TT] in K+ solution (43).
Telomestatin (Figure 1.11a), a macrocycle first isolated from Streptomyces
anulatus, inhibits the ability of telomerase to extend the TTAGGG telomeric repeat with
an IC50 of 5 nM without interfering with DNA polymerase activity. The proposed
mechanism of inhibition proceeds through the induction or stabilization of a basket type
16

antiparallel G-quadruplex with a 2:1 binding stoichiometry (2 equivalents of telomestatin
to 1 equivalent of a 3 tetrad G-quadruplex) (48, 49). Diseleno sapphyrin (Figure 1.11c)
binds to G-quadruplex DNA with a 1:1 stoichiometry and was found to convert
preformed a preformed antiparallel basket type G-quadruplex to a hybrid, mixed
parallel/antiparallel G-quadruplex (49). Braco-19 (Figure 1.11d), an aminoacridine based
selective telomerase inhibitor, has been shown to cause growth inhibition in tumor cell
lines as well as p21 and p53 mediated apoptosis (50).
TMPyP4 (Figure 1.11b), while not a serious drug candidate, has been extensively
studied as a model G-quadruplex binding molecule and is the basis for many Gquadruplex binding studies. Han et al. found that binding of the cationic porphyrin
proceeds via an n+1 stoichiometry, where n is the number of tetrads present in a Gquadruplex (51). For a G-quadruplex containing three tetrads, the binding stoichiometry
was found to be 4:1 (4 equivalents of TMPyP4 to 1 equivalent of a 3 tetrad Gquadruplex) and to proceed through two distinct binding modes. The first binding mode
is driven by a favorable enthalpy change and proposed to be end-stacking, whereas the
second mode is entropically driven and proposed to proceed through intercalation of the
porphyrin between the tetrads of the G-quadruplex (52). Binding of TMPyP4 to a Gquadruplex forming sequence shifts the equilibrium between duplex and G-quadruplex
formation for the binding of the G-quadruplex forming sequence to its complementary
strand towards that of the G-quadruplex, effectively lowering the affinity of the Gquadruplex forming sequence for that of its complementary mate by 30% and slowing the
rate constant for duplex formation by 32% (53).

17

Figure 1.11

Chemical structures for the G-quadruplex interacting compounds: A)
Telomestatin B) TMPyP4 C) Diseleno sapphyrin (Se2SAP) D) Braco-19.

These G-quadruplex binding agents exhibit the general planar conjugated or aromatic
core necessary for π-π stacking with the guanine residues of the quadruplex. Additionally
TMPyP4, Se2SAP, and Braco-19 display additional cationic charges that are able to offer
additional binding stability through ionic interaction with the DNA’s negatively charged
phosphate backbone (47-53).

1.4.3
1.4.3.1

The implications of the interactions of G-quadruplex binding ligands with
G-rich oncogenes
c-MYC NHE-III1 G-quadruplex studies
The c-MYC proto-oncogene promoter c-MYC nuclease hypersensitivity element

III1 (c-MYC NHE III1, Figure 1.12) is responsible for 80-90% of all c-MYC transcription
(54). It is composed of a guanine (and complementary cytosine) rich sequence capable of
18

forming G-quadruplex (and complementary I-motif) structures located -142 to -145 base
pairs upstream of the P1 promoter and has been proposed as a chemotherapeutic target
due to the overexpression of c-MYC in a variety of human cancer types including breast,
colon, and ovarian cancers (55). The overexpression of c-MYC in malignant cells is
precarious due to its role in regulating up to 15% of all gene expression (56). In the
presence of c-MYC, genes already upregulated in tumor cells are amplified to a greater
extent than gene with normal or low levels of expression (57).
The G-quadruplex forming ability of the c-MYC NHE III1, region and its
interactions with binding agents such as cationic porphyrins, has been investigated as a
means by which to control c-MYC expression (44, 58-61). In fact TMPyP4 is able to
suppress c-MYC transcription when the NHE-III1 region is present, allowing it to act as a
transcription silencing element. When the gene sequences lack the element, TMPyP4
does not suppress transcription, suggesting that G-quadruplex stabilizing compounds
could potentially be effective chemotherapeutic agents (62).
Binding of TMPyP4 to a model c-MYC sequence (5’GGGGAGGGTGGGGAGGGTGGGGAAGG-3’) proceeds through two distinct binding
modes, the first with an affinity of 5.4 *106 M-1 and the second with an affinity of 2.0
*105 M-1, as measured with isothermal titration calorimetry (ITC). Much like the
TMPyP4 binding events discussed earlier, the stronger binding event is driven by a
favorable change in entropy followed by a weaker event dependent on a favorable change
in enthalpy and a binding stoichiometry of 2:1 for the first mode and 2:1 for the second
mode. Titration experiments under varying salt concentrations show that as the
concentration of the supporting electrolyte increases the binding affinity decreases (61).
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Figure 1.12

Cartoon diagram showing the route of c-MYC transcription silencing by Gquadruplex stabilizing compounds. Reproduced from Brooks et al. with
permission (54).

A) The transcriptionally inactive form of the c-MYC NHE III1 oncogene promoter region
contains guanine and cytosine rich sequences which can form both G-quadruplex and Imotif structures, respectively. B) Resolution of the higher ordered DNA structures (Gquadruplex and I-Motif) by NM23-H2 allows c-MYC to transform into the
transcriptionally active form. C) The transcriptionally active form allows for the binding
of transcription factors to begin c-MYC transcription. D) A quadruplex binding protein
such as nucleolin (shown in orange) is able to lock c-MYC NHE III1 into the
transcriptionally inactive form by binding to the G-quadruplex. E) G-quadruplex
interactive compounds such as TMPyP4 can stabilize the c-MYC NHE III1 G-quadruplex,
also locking the promoter sequence in the transcriptionally inactive form (54).
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1.4.3.2

BCL-2 G-quadruplex studies
B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein coded for by the BCL-2

oncogene. Due to the overexpression of BCL-2 in number of cancers, malignant cells are
less likely to undergo apoptosis in these cancers with upregulated antiapoptotic factors.
This allows them to remain in a G0 state until upregulated oncogenes, such as c-MYC,
provide the necessary transcription factors to being replication (63). This BCL-2
upregulation has been proposed as a mechanism for the treatment resistance that often
arises during treatment in certain cancer types. The presence of a G-quadruplex forming
sequence in the promoter region, much like c-MYC, offers a potential chemotherapeutic
target for the downregulation of BCL-2 compounds are able to interact with and stabilize
the G-quadruplex (39).
Nagesh et al. has shown that TMPyP4 is able to interact with the BCL-2 promoter
sequence G-quadruplex (5’-CGGGCGGGGGAGGAAGGGGGCGGGAGC-3’) through
two distinct modes. Mode I exhibits a binding affinity of 4.2 * 107 M-1 and is driven by a
favorable change in entropy, suggesting end stacking, while mode II proceeds with an
affinity of 3.6 *105 M-1 and is characterized by a favorable change in enthalpy,
suggesting intercalation.
Planarity of the cationic porphyrin is necessary for optimum binding as reported
by Le et al. It was found that the sterically induced non-planarity of the methyl
pyridinium groups in TMPyP2 (Figure 1.13a) and TMPyP3 (Figure 1.13b) decreased the
binding affinity of the porphyrin/G-quadruplex complex with respect to the planar
TMPyP4. Additionally, the second binding mode of TMPyP4 (Figure 1.13c) type
association was not seen in the TMPyP2 and TMPyP3 experiments (52). The single
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binding mode seen for TMPyP3 and TMPyP2 associated proceeded through an
entropically driven binding process, suggesting that the non-planarity of the ligands
inhibits an intercalative binding mechanism (52, 64, 65).

Figure 1.13

1.5

A) Chemical structure of TMPyP2. B) Chemical structure of TMPyP3. C)
Chemical structure of TMPyP4.

Outline of this work
The work presented in this dissertation involved studying the binding of model

DNA binding small molecules (ligands) with DNA constructs to further understand how
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structural perturbations in model ligands affect the thermodynamics of the binding
process. The thermodynamic studies presented in this dissertation primarily use
isothermal titration calorimetry to analyze binding reactions to determine the full set of
thermodynamic parameters associated with those reactions. Supplemental analytical
techniques include UV-Vis and circular dichroism spectroscopies.
In Chapter 2, structural changes of a pyridinium substituted porphyrin core were
investigated to determine charge, size, shape, and symmetry affect the thermodynamic
parameters associated with the molecular recognition of planar aromatic molecules for Gquadruplex structures. This was performed by modulating the number or pyridinium
groups on the porphyrin core. Cationic porphyrins of higher symmetry (TMPyP4 and A2
trans) exhibited higher binding affinities against a model BCL sequence G-quadruplex
when compared with porphyrins of lower symmetry (A3 tris, A2 cis, and A1 mono).
Chapter 3 builds upon the study in Chapter 2 by investigating how substitution of
metals into the porphyrin core would affect binding. Porphyrins containing Cu2+ and Ni2+
metal centers, with no or only weakly bound axial ligands, bound to a model human
telomeric G-quadruplex with affinities equal to or greater than the unmetallated
porphyrin, whereas the porphyrins containing Co3+ and Zn2+, with one or two strongly
bound axial ligands, exhibited markedly decreased binding affinities and lower saturation
stoichiometries.
In Chapter 4, a series of cationic ruthenium containing polyheterocyclic
molecules starting with a positively charged minor groove binder and leading to
molecules with a greater intercalative abililty were investigated for their binding
properties with B-DNA. It was found that [Ru(phen)2t(tatpp)]2+ exhibited a higher
23

binding affinity than [(phen)2Ru(tatpp)Ru(phen)2]2+ for a model duplex, a likely source
for the better IC50 exhibited by [Ru(phen)2t(tatpp)]2+.
These studies have been successful in part in determining the contributions of
numerous weak interactions on the binding of ligands to model DNA constructs. The
binding of porphyrins to G-quadruplex DNA was found to be greatly affected by charge,
hydrophobic interactions, shape, symmetry, and solvent structure. Ruthenium(II)
compounds were found to bind more tightly as the length of the intercalator increased
(dependent on size, solvent accessible surface area, and π-bonding), but the additional
charge of the second ruthenium center in the binuclear complexes actually caused a
decrease in complex stability (dependent on charge and size).
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CHAPTER II
THE EFFECT OF PYRIDYL SUBSTITUENTS ON TH ETHERMODYNAMICS OF
PORPHYRIN BINDING TO G-QUADRUPLEX DNA
Previously published in Bioorganic & Medicinal Chemistry 2013, 21, 7515-7522
and reproduced with permission.
2.1

Abstract
Most of the G-quadruplex interactive molecules reported to date contain extended

aromatic flat ring systems and are believed to bind principally by π-π stacking on the end
G-tetrads of the quadruplex structure. One such molecule, TMPyP4, (5,10,15,20-tetra(Nmethyl-4-pyridyl)porphyrin), exhibits high affinity and some selectivity for Gquadruplex DNA over duplex DNA. Although not a realistic drug candidate, TMPyP4 is
used in many nucleic acid research laboratories as a model ligand for the study of small
molecule G-quadruplex interactions. This work reports on the synthesis and Gquadruplex interactions of four new cationic porphyrin ligands having only 1, 2, or 3 (Nmethyl-4- pyridyl) substituents. The four new ligands are: P(5) (5-(N-methyl-4pyridyl)porphyrin), P(5,10) (5,10-di(N-methyl-4-pyridyl)porphyrin), P(5,15) (5,15-di(Nmethyl-4-pyridyl)porphyrin), and P(5,10,15) (5,10,15-tri(N-methyl-4-pyridyl)porphyrin).
Even though these compounds have been previously synthesized, alternative synthetic
routes that are more efficient and that result in higher yields were utilized. ITC, CD, and
ESI-MS were used to explore the effects of the number of N-methyl-4-pyridyl
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substituents and the substituent position on the porphyrin on the G-quadruplex binding
energetics. The relative affinities for binding these ligands to the WT Bcl-2 promoter
sequence G-quadruplex are: KTMPyP4 ≈ KP(5,15) > KP(5,10,15) >>> KP(5,10), KP(5). The
saturation stoichiometry is 2:1 for both P(5,15) and P(5,10,15), while neither P(5) nor
P(5,10) exhibit significant complex formation with the WT Bcl-2 promoter sequence Gquadruplex. Additionally, binding of P(5,15) appears to interact by an “intercalation
mode” while P(5,10,15) appears to interact by an “end-stacking mode”.
2.2

Introduction
Over expression of BCL-2 has been observed in a number of cancers including:

breast, prostate, cervical, colorectal, and lung carcinoma (1). The human BCL-2 P1
promoter region is GC-rich and the G-rich strand is known to form a stable Gquadruplex structure (2). The stabilization of oncogene promoter sequence Gquadruplexes and telomere overhang repeat sequence G-quadruplexes by binding small
molecules (e.g. ligands or drugs) is a subject of interest in cancer drug discovery.
Ligands exhibiting structural recognition (selectivity) and high affinity for G-quadruplex
DNA including several porphyrin based compounds have been explored for their
potential as anti-cancer drugs (3-6). The porphyrin-based ligands have shown the ability
to inhibit telomerase and they typically exhibit low cytotoxicity (5, 6). TMPyP4,
(5,10,15,20-tetra(N-methyl-4-pyridyl)porphyrin), while not a serious drug candidate,
has been used extensively as a model ligand in the characterization of the structure,
stability, and ligand binding properties of oncogene promoter sequence G-quadruplexes
(5-14).
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The Lewis group has published several studies on the interactions of TMPyP4
with several oncogene promoter sequence G-quadruplexes including c-MYC, BCL-2, and
K-ras (7-11). The Lewis group has also shown that that TMPyP4 binding to these Gquadruplexes results in a complex having 4 moles of TMPyP4 per mole of quadruplex
and that the complex is stabilized significantly over the naked G-quadruplex. TMPyP4
binds to these G-quadruplexes by two distinctly different binding modes, a higher affinity
mode which is driven by a favorable entropy change and a weaker mode which is
accompanied by an unfavorable entropy change. We believe that these two modes
represent first the end-binding of two moles of TMPyP4 followed by the intercalation of
another two moles of TMPyP4 so that every G-tetrad is sandwiched between two planar
porphyrin molecules. Le et al. recently reported on a study of the interactions of three
related porphyrins, (TMPyP2, TMPyP3, and TMPyP4), with a WT 39-mer Bcl-2
promoter sequence G-quadruplex (7). Using CD, Fluorescence, ITC, and ESI-MS, it was
shown that as the substituted porphyrin becomes non-planar, the intercalation binding
mode is eliminated so that the saturation stoichiometry for binding TMPyP2 or TMPyP3
becomes 2:1 (15). In addition, the end-stacking mode is also weakened as the porphyrin
ligand becomes increasingly less planar with the binding of TMPyP2 << TMPyP3.
TMPyP4 like many other G- quadruplex interactive ligands reported to date are planar
heterocyclic aromatic ring systems (16-25). The porphyrin ligand charge (e.g. +1, +2,
+3, or +4), size (e.g. SASA (solvent accessible surface area)), shape (e.g. planarity) and
symmetry (e.g. substitution pattern) may all play a role in establishing the selectivity and
affinity for G-quadruplex complex formation. This study has begun to explore each of
these effects by synthesizing new ligands that are systematically reduced in size, charge,
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and symmetry in comparison to TMPyP4. The new ligands differ from the model
TMPyP4 quadruplex interactive compound by having only one, two, or three (N-methyl4-pyridyl) substituents.
ITC, CD, and ESI-MS were used to study the interactions of these new porphyrin
ligands with a 27-mer WT BCL-2 P1 promoter sequence G-quadruplex. Although
Goncalves et al. has already reported the synthesis for the P(5) (5-(N-methyl-4pyridyl)porphyrin), P(5,10) (5,10-di(N-methyl-4-pyridyl)porphyrin), P(5,15) (5,15di(N-methyl-4-pyridyl)porphyrin), and P(5,10,15) (5,10,15-tri(N-methyl-4pyridyl)porphyrin) compounds (26), this work presents alternative synthetic routes that
are more efficient and that result in higher yields. Goncalves et al. also reported SPR
experiments from which they estimated the binding affinities for these same four ligands
with a human telomere repeat sequence G-quadruplex (26). In these experiments, the Gquadruplex is different, but even more importantly, the complete set of thermodynamic
parameters for the formation of these four porphyrin ligand complexes with a typical
oncogene promoter sequence G-quadruplex have been determined. The ITC, CD, and
ESI-MS data reported here have been analyzed to yield values for the free energy
changes (ΔG), the enthalpy changes (ΔH), the entropy changes (-TΔS), and the saturation
stoichiometry (n) for the formation of the WT BCL-2 27-mer P1 promoter sequence Gquadruplex complexes with P(5), P(5,10), P(5, 15) and P(5,10,15).
2.3
2.3.1

Materials and Methods
Binding studies
The WT 27-mer BCL-2 oligonucleotide used in this study was obtained from

Midland Oligos (Midland, TX). The oligonucleotide has the following sequence 5’34

CGG GCG CGG GAG GAA GGG GGC GGG AGC -3’. DNA stock solution was
prepared by reconstituting the lyophilized oligonucleotide into KBPES buffer with a salt
concentration of 130 mM [KCl] and a pH of 7.0. Approximately 2 mL of the
oligonucleotide was dialyzed (1000 MW cutoff membrane) against three changes of
buffer solution (1 L, 24 h each) at 4 °C. The concentrations of stock DNA solution were
verified using UV-Vis. DNA was annealed by quickly heating the sample to 100 °C,
holding at 100 °C for ten minutes then slowly cooling to 5 °C over a three hour period.
The molar extinction coefficient of the DNA was determined using a nearest-neighbor
method for single stranded DNA (27). The extinction coefficient at 260 nm for the WT
27-mer Bcl-2 sequence was: 2.26×105 M-1 cm-1.
CD experiments were performed with an Olis DSM-20 spectropolarimeter
(Bogart, GA). All measurements were done at 25 °C using a 1 cm quartz cuvette and
covering a spectral range of 225-325 nm. All CD samples were prepared such that they
had a nominal absorbance of less than 1.0 at 260 nm.
ITC experiments were performed using a VP-ITC calorimeter (GE-Healthcare).
A typical ITC experiment involved the addition of 28 (10 μL) injections of a dilute (115
μM) WT 27-mer Bcl-2 DNA solution into ~ 1.5 mL of a dilute porphyrin solution (5 μM).
Reverse titrations were employed because of the low solubility of the substituted
porphyrins. Three replicate experiments were done for each of the four porphyrins. Blank
titrations were done by injecting the titrant (115 μM G-quadruplex) into buffer solution.
Corrected titration curves were achieved by subtracting the blank titration data from the
ITC data for the porphyrin-DNA titrations. Corrected ITC titrations were fit with a
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nonlinear regression algorithm again using the CHASM© ITC data analysis program
developed in the Lewis laboratory (28).
ESI-MS experiments on BCL-2 and the BCL-2 porphyrin complexes were carried
out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in
negative ion mode. All experiments were performed in 50 mM ammonium acetate buffer
(pH = 7.0) containing 20% HPLC grade methanol. The WT Bcl-2 27-mer G-quadruplex
sample was prepared at a concentration of approximately 25 μM in the ammonium acetate
buffer and was dialyzed against three changes of buffer 12 hours each at 4 °C. Stock
solutions of the porphyrin ligands were prepared in the final dialysate buffer at
concentration as high as 50 μM. The ESI-MS samples were prepared by mixing the DNA
and ligand stock solutions to yield a mixture containing 4 equivalents of each porphyrin
ligand per equivalent of DNA. The MS capillary voltage was set to +3500 V, dry N2 gas
flow was adjusted to 0.5 L/min at 110°C, and the G-quadruplex/porphyrin samples were
directly infused into the MS by using a kD Scientific syringe pump set to a flow rate of
200 µL/hour. Data processing was performed by using Bruker Daltonics Data Analysis
program.
2.3.2

Porphyrin ligand synthesis
The overall synthesis for the four porphyrin ligands studied here is shown in

Scheme 2.1. The synthesis of the substituted porphyrins began by synthesizing the key
dipyrromethane building blocks 1 and 4 by condensation of the respective aldehydes
with pyrrole (29, 30). Formylation of 1 utilizing a Vilsmeier reaction gave compound 2
in 45% yield (26). Functionalized dipyrromethane 5 was synthesized by the
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diformylation of pyridyl dipyrromethane 4 also utilizing a Vilsmeier reaction in 28%
yield (26). The reduction of formylated dipyrromethane 5 with sodium borohydride
provided compound 6, which was used in subsequent steps without purification (26).
With the key building blocks in hand, the synthesis was directed to the desired
porphyrin analogues. The synthesis of P(5) was accomplished by the condensation of
dipyrromethanes 1 and 6 in the presence of trifluoroacetic acid. The resulting mixture
was allowed to stir for one hour, oxidized with DDQ, and treated with triethylamine to
provide porphyrin 7 in 8% yield. Methylation of 7 with iodomethane followed by
washing with ether provided P(5) in 16% yield (26).
The synthesis of P(5,10) was accomplished by deprotonation of compound 6
with ethyl magnesium bromide followed by the addition of Mukiyama reagent 8 resulted
in the formation of compound 9 in 41% yield (31). The condensation of compounds 2
and 9 resulted in the formation of porphyrin 10 in 35% yield (32). Methylation of 14
provided the P(5,10) in 6% yield (26).
Porphyrin P(5,15) was synthesized by the condensation of compound 4 with
trimethyl orthoformate 11 followed by methylation provided P(5,15) in 2% overall yield.
Condensation of compounds 3, 4, and 11 followed by methylation resulted in the
formation of porphyrin P(5,10,15) (26).
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Scheme 2.1

Synthetic routes for the four cationic porphyrin ligands used in this study
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2.3.2.1

Dipyrromethane 1 (30):
Paraformaldehyde (1.73g, 57.7mmol) and pyrrole (100mL, 1.44 mol) were added

to a 250mL two-necked round-bottom flask equipped with a condenser and an internal
thermometer. The mixture was brought to an internal temperature of 65 °C. The flask was
removed from the heat and TFA (444 μL, 5.77 mmol) was added. The mixture was
purified via flash chromatography eluting at 8-10% EtOAc in hexanes affording 3.17g of
1 as a white solid in 37% yield. 1H NMR (300MHz, DMSO-d6): δ = 3.807 (s, 2H), 5.744
(s, 2H), 5.884-5.893 (d, 2H), 6.583 (s, 2H), 10.502 (br s, 2H).
2.3.2.2

1-formyl dipyrromethane 2 (26):
DMF (24.2 mmol, 1.9 mL) was added to a dry RBF and cooled to 0 °C. POCl3

(0.3 mL, 3.01 mmol) was added drop wise and stirred for 10 min to yield the Vilsmeier
reagent. In another dry RBF, dipyrromethane 1 (0.500 g, 3.42 mmol) was dissolved in
DMF (7.5 mL) under argon and cooled to 0 °C. To the reaction mixture, the freshly
prepared Vilsmeier reagent (1.9 mL, 3.36 mmol,) was added drop wise and stirred at 0 °C
for 2 h. After 2 h, a biphasic solution of ethyl acetate (50 mL) and saturated aqueous
sodium acetate (50 mL) was added and stirred at room temperature for 4 h. Ethyl acetate
was separated and the aqueous layer was extracted three times with ethyl acetate and the
combined organic layer was washed with brine and water, dried over anhydrous Na2SO4
and evaporated in vacuo to get crude product. The desired compound was isolated using
automated flash chromatography, eluting at 20% EtOAc in DCM and evaporate in vacuo
to yield 2 as a pale yellow solid (270 mg, 45.2%). 1HNMR (300 MHz, DMSO-d6): δ =
11.93 (br s, 1H), 10.606 (br s, 1H), 9.328 (s, 1H), 6.867-6.887 (m, 1H), 6.602-6.607 (m,
1H), 5.98-5.999 (m, 1H), 5.866-5.892 (m, 1H), 5.765 (br s, 1H), 3.868 (s, 2H) ppm.
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2.3.2.3

5-(4-pyridyl) dipyrromethane 4 (29):
4-pyridylcarboxaldehyde 3 (1.5mL, 16.4 mmol) and pyrrole (16mL, 230 mmol)

were added to a microwave vial. The vial was sealed under argon and stirred for 20 min
at 150 °C. The reaction mixture was cooled and concentrated under reduced pressure to
yield a dark red liquid which was left on high vacuum overnight to yield a dark oil. The
oil was dissolved in minimal DCM and wet-loaded onto a Biotage 50G column, packed
with alumina oxide and purified via flash chromatography with DCM: EtOAc. Fractions
containing product were collected and concentrated under vacuum. Minimal DCM was
added to the resulting solid to create a slurry. Excess hexanes were added and the mixture
was filtered, collecting 4 as a pale grey solid (645.1mg, 18.9% yield).

1

H NMR

(300MHz, CDCl3): δ = 5.541 (s, 1H), 5.874 (s, 2H), 6.168-6.197 (q, 2H), 6.738-6.761 (q,
2H), 7.313-7.340 (d, 2H), 7.599-7.627 (d, 2H), 7.973 (br s, 2H).
2.3.2.4

1,9-Diformyl-5-(4-pyridyl)dipyrromethane 5 (26):
The procedure of 1-formyldipyrromethane 2 was followed with DMF (6 mL, 58

mmol), POCl3 (0.9 mL, 9.66 mmol) and replacing the dipyrromethane with 5-(4-pyridyl)
dipyrromethane 4 (0.300 g, 1.34 mmol). The desired compound was isolated using
automated flash chromatography, eluting at 9% MeOH in DCM and concentrated in
vacuo to yield 5 as a brown oil (0.103 g, 28%). 1HNMR (300 MHz, CDCl3), δ = 10.96 (br
s, 2H), 9.24 (s, 2H), 8.58 (d, J = 5.1 Hz, 2H), 7.28 (d, J = 5.1 Hz, 2H), 6.91 (s, 2H), 6.09
(s, 2H) and 5.60 (s, 1H) ppm.
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2.3.2.5

(5,5’-(pyridine-4-ylmethylene)bis(1H-Pyrrole-5,2-diyl)dimethanol 6
(26):
In a dry RBF under argon, 1,9-Diformyl-5-(4-pyridyl)dipyrromethane 5 (0.103 g,

0.365 mmol) was dissolved in THF-Methanol (10:1, 20 mL) and cooled to 0 °C. NaBH4
(0.29 g, 7.66 mmol) was added in roughly 50 mg portions every 2 min under a stream of
argon. The reaction mixture was stirred at room temperature for 1 h and poured into a
biphasic mixture of saturated aqueous ammonium chloride and DCM (1:1, 50 mL). The
organic layer was washed with water twice and dried over anhydrous Na2SO4 and
evaporated in vacuo to get crude 6 (100 mg) which was used directly in the next step.
2.3.2.6

4-Pyridylporphyrin 7 (26):
1 was added to the above 6 and stirred at room temperature for 5 min. TFA

(0.33 mL, 4.39 mmol) was added and the mixture was stirred for 1 h. DDQ (0.247 g,
1.09 mmol) in toluene (6 mL) was added and stirred for1 h. Triethylamine (0.6 mL, 4.39
mmol) was added and stirred for 10 min. The reaction mixture was evaporated in vacuo.
Crude 7 was isolated at 2-10% MeOH in DCM as a purple solid (150 mg) using flash
chromatography and purified by preparative TLC (eluted by 5% MeOH in DCM). The
purple band was collected and extracted from the silica with MeOH. Evaporation of the
solvent in vacuo gave 7 as a purple-red solid (6 mg, 8%). 1HNMR (600 MHz, DMSOd6): δ = 10.70 (s, 2H), 10.64 (s, 1H), 9.74-9.72 (m, J = 4.4 Hz, 6H), 9.33 (d, J = 5.9 Hz,
2H), 9.27 (d, J = 4.4 Hz, 2H), 8.92 (d, J = 5.9 Hz, 2H) and -3.57 (br s, 2H, NH) ppm.
2.3.2.7

S-2-Pyridyl isonicotinothioate 8 (31,32):
An oven dried flask was charged with 2-mercaptopyridine (1.000 g, 8.99 mmol)

and purged with argon. The solid was dissolved in anhydrous THF (20 mL) with stirring.
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The solution was treated with isonicotinoyl chloride hydrochloride (1.600 g, 8.99 mmol).
The resulting slurry was stirred overnight. The reaction mixture was filtered. The filtrate
was washed with hexanes. The resulting orange solid was added to a biphasic solution of
diethyl ether and saturated sodium bicarbonate and stirred until it no longer bubbled. The
organic layer was collected and the aqueous layer was washed with diethyl ether (3 x 50
mL). The organic layers were combined and dried with Na2SO4 and concentrated in
vacuo to yield a yellow solid. Minimal THF was added to the solid to form a slurry which
was filtered and washed with hexanes to yield 8 (0.8 g, 45%). 1HNMR (300 MHz,
DMSO-d6): δ = 8.65 (m, 2H), 8.719 (m, 1H), 7.820-7.854 (m, 3H), 7.749 (d, J = 7.8 Hz,
1H), 7.40 (m, 1H).
2.3.2.8

1-Isonicotinoyl-5-(4-pyridyl) dipyrromethane 9 (31,32):
To a solution of 6 (0.844 g, 3.8 mmol) in THF (15 mL) under argon was added

dropwise 1.0 M EtMgBr (9.6 mL, 9.6 mmol) at room temperature. The flask was stirred
for 10 min and cooled to -78 °C. S-2-pyridyl isonicotinothioate (0.795 g, 3.7 mmol) in
THF (15 mL) was added dropwise over 10 min and stirred for an additional 10 min
before warming to RT and stirring for 4 h. The reaction was quenched at RT with 25 mL
saturated aqueous NH4Cl. The slurry was extracted with EtOAc (3 x 25 mL). The
organic layer was washed with DI water (3 x 20 mL), brine (3 x 20mL), dried with
Na2SO4 and evaporated in vacuo to yield a yellow-brown solid. Flash chromatography
gave 9 (0.506, 1.54 mmol) as a light brown solid in 41% yield eluting at 12% MeOH in
DCM. 1HNMR (300 MHz, DMSO-d6): δ = 12.290 (br s, 1H), 10.809 (br s, 1H), 8.738
(d, J = 4.8, 2H), 8.493 (d, J = 4.8), 7.650 (d, J = 4.8), 7.159 (d, J = 4.8, 2H), 6.774 (m,
1H), 6.693 (m, 1H), 6.067 (m, 1H), 5.942 (m, 1H), 5.761 (m, 1H), 5.601 (s, 1H).
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2.3.2.9

5,10-Di(4-pyridyl)porphyrin 10 (32):
To a stirred solution of 1-formyldiprromethane 2 (0.018 g, 0.103 mmol) and 1-

isonicotinoyl-5-(4-pyridyl) dipyrromethane 9 (0.035 g, 0.106 mmol) in 2.4 mL toluene
in a microwave reactor vial was added DBU (0.35 ml, 2.3 mmol) and stirred for 10 min.
MgBr2 (0.125 g, 0.67mmol) was added to the vial, which was then capped in atmosphere
and heated to 115 °C for 90 min in the microwave reactor with magnetic stirring. The
vial was emptied and rinsed with THF into a pear-shaped flask and evaporated. The
crude solid was dissolved in DCM (15 mL) and washed with DI water (2 x 30 mL) and
brine (2 x 30mL) dried with Na2SO4 and evaporated. The solid was dissolved in 4 mL
DCM and demetallated with trifluoroacetic acid (0.050 mL) and neutralized with
triethylamine (0.040 mL). After 5 min the mixture was washed with DI water (1 x 10
mL) and brine (2 x 10 mL), dried with Na2SO4 and evaporated to dryness. The crude
product was then purified by column chromatography eluting at 45-50% MeOH in
EtOAc. Evaporation of the solvent gave 10 (0.017g) in 35% yield.

1

HNMR (300 MHz,

CDCl3): δ = 10.341 (s, 2H), 9.519 (s, 2H), 9.439 (m, 2H), 9.079 (m, 4H), 9.012 (m, 2H),
8.936 (s, 2H), 8.206 (m, 4H), -3.422 (s, 2H).
2.3.2.10

5,15-Di-(4-pyridyl)porphyrin 12 (26):
5-(4-pyridyl) dipyrromethane 4 (1.000 g, 4.51 mmol), trimethyl orthoformate 11

(36 mL, 329 mmol) and DCM (700 mL) were added to a flask covered with aluminum
foil, stirred and degassed by bubbling with argon for 30 min. A solution of TCA (17.6 g,
108 mmol) in DCM (300 mL) was added drop wise to the flask over 15 min. The
reaction was stirred under argon for 4 h. The mixture was quenched with pyridine (31.2
mL) and stirred for 18 h. The reaction mixture was bubbled with air for 10 min. The
43

aluminum foil was removed and the reaction was stirred under ambient light for 4 h. The
solvent was removed in vacuo to yield a black solid. The solid was filtered through a
silica pad, and washed with DCM and 0.5% MeOH in DCM. The fraction collected was
concentrated in vacuo and dissolved in DCM and filtered through a Buchner funnel to
eliminate some black solid. The filtrate was concentrated to 3 mL and wet loaded onto a
flash chromatography column. Automated flash chromatography gave pure fractions at
1% MeOH in DCM. Fractions were collected and concentrated in vacuo to afford 12 as a
purple solid (80 mg, 4%). 1H NMR (300 MHz, CDCl3): δ = 10.416 (s, 2H), 9.485 (d, J =
4.65, 4H), 9.11 (m, 4H), 9.075 (d, J = 4.67, 4H), 8.260 (m, 4H).
2.3.2.11

5, 10, 15-Tri-4-pyridylporphyrin 13 (26):
5-(4-pyridyl)dipyrromethane 4 (500 mg, 2.3 mmol), trimethyl orthoformate 11

(9 mL, 82.5 mmol), 4-pyridylcarboxaldehyde 3 (0.4 mL, 4.1 mmol) and anhydrous
DCM (400 mL) were added to a flask and degassed by bubbling with argon for 30 min.
In a separate flask, TCA (8.83 g, 54 mmol) was dissolved in anhydrous DCM (100 mL).
The solution was added to the reaction mixture slowly over 15 min and stirred for 4 h.
The reaction mixture was quenched with pyridine (15.6 mL) and stirred for 2 h. DDQ
(0.3 g, 1.3 mmol) was added and stirred for 15 min. The aluminum foil was removed and
the solvent was evaporated in vacuo to yield a black solid, which was left on high
vacuum overnight. The black solid was preadsorbed onto silica and purified twice via
automated flash chromatography using 5% MeOH in DCM. Preparative TLC, run in 8%
MeOH in DCM gave 13 as a purple band, isolated as a purple solid (15 mg, 1.3%). 1H
NMR (300 MHz, CDCl3) : δ = 10.355 (s, 1H), 9.436 (d, J = 4.7 Hz, 2H), 9.081 (m, 6H),
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9.032 (d, J = 4.7 Hz, 2H), 8.923 (m, 4H), 8.218 (m, 6H), -3.118 (s, 2H). Exact mass:
calculated: 542.21; found: 542.2071 (M+H+)
2.3.2.12

General procedure for the quaternization of porphyrin pyridyl groups
with iodomethane (26):

To an oven dried flask cooled under vacuum porphyrin (0.044 mmol) was added
and purged with 3x with argon. 32 mL dry CHCl3 followed by 8 mL dry DMF was
added via syringe. 3.5 mL (excess) CH3I was added and the solution was stirred for 12
hours at RT. The solution was concentrated under vacuum to 1/4 the original volume. To
the solution was then added 60 mL Et2O several times with subsequent decanting. The
solid was then triturated with CH3CN, decanted and dried in vacuo to yield product.
2.3.2.12.1

5-(N-methylpyridynium-4-yl) porphyrin P(5):

Trituration yielded 0.002 g P(5). Exact mass: calculated: 402.1713; found:
402.1771.
2.3.2.12.2

5,10-Di(N-methylpyridinium-4-yl) porphyrin P(5,10):

Note that P(5,10) was soluble in CH3CN, so the last wash was filtered and
evaporated to dryness to yield 0.001 g P(5,10). Exact mass: calculated: 494.2200; found:
494.2140.
2.3.2.12.3

5,15-Di(N-methylpyridinium-4-yl)porphyrin P(5,15):

Trituration yielded 0.012 g P(5,15). 1H NMR (300 MHz, DMSO-d6): δ = 10.849
(s, 2H), 9.859 (d, J = 4.7, 4H), 9.516 (d, J = 5.91, 4H), 9.245 (d, J = 4.7, 4H), 9.083 (d, J
= 5.92, 4H), 4.745 (s, 6H), -3.333 (br s, 2H). Exact mass: calculated 494.2200; found:
494.2228.
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2.3.2.12.4

5,10,15-tri(N-methyl pyridinium-4-yl)porphyrin P(5,10,15):

Trituration yielded 0.008 g P(5,10,15). 1H NMR (300 MHz, CDCl3): δ =
10.866 (s, 1H), 9.860 (br s, 2H), 9.518 (m, 6H), 9.210 (m, 4H), 9.183 (m, 2H), 9.030
(m, 4H), 8.970 (m, 2H), 4.981 (s, 9H), -3.660 (s, 2H). Exact mass: calculated:
195.4200; found: 195.4242.
2.4

Results
The CD spectra shown in Figure 2.1 indicate that the WT Bcl-2 27-mer P1

promoter sequence exists as a mixed parallel/anti-parallel G-quadruplex in the K+ BPES
buffer in the absence of any added porphyrin ligand. The naked Bcl-2 27-mer CD
spectrum shown in the Figure 2.1, (P/DNA = 0), exhibits typical G-quadruplex
characteristic peaks and troughs at 245 nm, 265 nm and a shoulder at 290 nm (8). The
dashed line shown along the x-axis in Figure 2.1 is the measured ellipticity of the
porphyrin in a DNA free solution. The CD spectra for the P(5,10,15)/Bcl-2 complexes
having porphyrin to DNA ratios of 1, 2, 3, or 4 show that the CD signal for the Gquadruplex is largely the same for the complexes and the naked DNA although there is
some attenuation of the characteristic peaks and troughs in the complex spectra. It is
obvious that binding P(5,10,15) to the WT Bcl-2 27-mer P1 promoter sequence Gquadruplex does not perturb the folding of the DNA in the G-quadruplex. The CD
spectra shown in Figure 2.2 are for the 2:1 complexes of the Bcl-2 G-quadruplex with
P(5,15), P(5,10,15) and TMPyP4 (P(5,10,15,20)). The CD spectra shown in Figure 2.2
indicate that there is no change in the G-quadruplex structure upon complex formation
with these ligands.
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Figure 2.1

CD spectra of WT 27-mer Bcl-2 G-quadruplex in the absence and presence
of the P(5,10,15) ligand.

The ellipticity at 265 nm is attenuated progressively as the porphyrin to DNA ration is
increased from 0 to 4. The dashed line near y=0 is the ellipticity for the P(5,10,15) in a
DNA free solution
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Figure 2.2

CD spectra are shown for the Bcl-2 G-quadruplex and its 2:1 complexes
with P(5,15), P(5,10,15) and TMPyP4.

The ellipticities at 265 nm and 295 nm are essentially the same for all three ligands and
the free Bcl-2 G- quadruplex.
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Figure 2.3

Electrospray ionization mass spectra for WT 27-mer Bcl-2 G-quadruplex
and its complexes with P(5), P(5,10), P(5,15), and P(5,15,20).

Panel A shows the mass spectrum obtained for a solution containing only the Bcl-2
oligonucleotide at a concentration of 10 μM. Panels B–E show the mass spectra for the
Bcl-2 oligonucleotide and its porphyrin complexes obtained in solutions containing 40
μM P(5), 40 μM P(5,10), 40 μM P(5,15) and 40 μM P(5,15,20), respectively.
The ESI mass spectrum for the WT Bcl-2 27-mer P1 promoter sequence Gquadruplex, and the spectra for the saturated complexes of the WT Bcl-2 27-mer P1
promoter sequence G-quadruplex with P(5), P(5,10), P(5, 15) and P(5,10,15) are shown
in Figure 2.3. The ESI mass spectra for the solutions containing P(5) or P(5,10) along
with the Bcl-2 G-quadruplex, shown in Figure 2.3 B and C respectively, provide no
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evidence for Bcl-2 complex formation with these ligands. The only peaks in the mass
spectra shown in Panel B and Panel C of Figure 2.3 are for the parent DNA with a charge
of -5 or -4, exactly the same as the spectrum shown in Panel A for the naked DNA. The
ESI mass spectrum for the solution containing P(5,15) along with the Bcl-2 G-quadruplex
is shown in Panel D of Figure 2.3. The spectrum for this solution which contains four
moles of P(5,15) per mole of Bcl-2 G-quadruplex is consistent with significant complex
formation. The new peaks with m/z values of 1908.3 and 2385.6 are attributed to a
P(5,15)/Bcl-2 complex having a molar ratio of 2:1 and a charge of -5 or -4 respectively.
It should also be noted that no free or uncomplexed Bcl-2 is present in this solution. This
result is consistent with a very large Ka for formation of the 2:1 P(5,15)/Bcl-2 complex.
The ESI mass spectrum for the solution containing P(5,10,15) and the Bcl-2 Gquadruplex is shown in Panel E of Figure 2.3. The spectrum for this solution, which
contains four moles of P(5,10,15) per mole of Bcl-2 G-quadruplex, is consistent with
weaker complex formation. The new peaks with m/z values of 1947.4 and 2436.2 are
attributed to a P(5,10,15)/Bcl-2 complex having a molar ratio of 2:1 and a charge of -5 or
-4. In this spectrum a peak with an m/z value of 1711.2 which corresponds to
uncomplexed G-quadruplex with a charge of -5 is also seen. The same peak (m/z =
1711.2) is also seen as the predominant peak in the spectrum obtained for DNA in the
ligand free solutions (Figure 2.3 Panel A). The ESI-MS spectra were obtained using
ammonium acetate as the buffer and supporting electrolyte (in place of either Na+ or K+).
The greater lability of the ammonium ion in comparison to either sodium or potassium
ions reduces DNA counter ion adduction yields a cleaner mass spectrum. Under these
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conditions, the observation of the loss of the two NH4+ from between the stacked Gtetrads in the quadruplex is problematic.
Due to the limited solubility of the P(5), P(5,10), P(5,15) and P(5,10,15)
porphyrin ligands, the ITC experiments were all done as reverse titrations in which a
dilute solution of the DNA was added to a dilute solution of the porphyrin in the
calorimeter cell (see Figure 2.4). Reverse titration is a common practice for systems with
low solubility and yields thermograms that are easily fit to an independent site model with
the CHASM© program (28) (see ITC data in Figure 2.4 panel C). Typical ITC data for
the titration of the P(5,15) porphyrin ligand with the Bcl-2 G-quadruplex are shown in
Figure 2.4 panel A. The data shown in Figure 2.4 panel B are for the dilution of P(5,15),
i.e. the curve shown is for the addition of buffer to the P(5,15) porphyrin titrate. The
heats of dilution for these porphyrins were significant, a sign that the porphyrins in
solution are undergoing some self-association. The data shown in Figure 2.4 panel C are
the integrated heat data corrected for the heat of dilution. The best fit parameters and
associated uncertainties for the non-linear regression fit of the ITC heat data are shown in
the box in Figure 2.4 C. The expected value of n would be 0.5 for a complex having two
ligands per mole of DNA since these data are for the reverse titration. The ITC data for
the P(5,15) and P(5,10,15) titrations were similar in that these two ligands bind with
similar stoichiometry (2:1) and similar affinity (Ka ≈ 1×107). The ITC data for the P(5)
and P(5,10) titrations were similar in that these two ligands were not observed to bind and
the titrations were almost identical to the blank titrations. The corrected data for the
P(5,15) and P(5,10,15) titrations were fit with CHASM© to yield best fit values for K,
ΔH, and n. Values of ΔG and -TΔS were calculated from the best fit parameters and are
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reported in Table 2.1. The relative affinities for binding the four new porphyrin ligands
and TMPyP4 to the WT Bcl-2 promoter sequence G-quadruplex are: KTMPyP4 ≈ KP(5,15) >
KP(5,10,15) >>> KP(5,10), KP(5). The ITC and ESI-MS data are in agreement with respect to
the relative affinities

Figure 2.4

Panel A shows the thermogram for the addition of the 115 μM WT-27mer
Bcl-2 titrant into 5 μM P(5,15), Panel B shows the thermogram for heat of
dilution of the porphyrin solution, that is, the addition of buffer into 5 μM
P(5,15), and Panel C shows the corrected enthalpogram for titration DNA
into porphyrin ligand along with the model fit (▬) and best fit parameters
for formation of the 2:1 complex.
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Table 2.1

A Comparison of the thermodynamic parameters for binding the porphyrin
ligands P(5), P(5,10), P(5,15), P(5,10,15) and TMPyP4 to G-quadruplex
DNA.

a

The SPR data are for the interaction of the porphyrin ligands with a 26-mer human
telomere G-quadruplex having the sequence: 5’-GGA TTG GGA TTG GGA TTG GGA
TTG GG-3’ (26)
b
The ITC data reported here are for the interaction of the porphyrin ligands with a 27mer BCL-2 G-Quadruplex having the sequence: 5’-CGG GCG CGG GAG GAA GGG
GGC GGG AGC-30. The data for the binding of TMPyP4 to the same G-quadruplex are
from Nagesh et al. (9)
2.5

Discussion
The synthetic routes for all four model porphyrin ligands are shown in Scheme

2.1 and all previous synthesis and synthetic methods are referenced. The synthesis of
porphyrins P(5), P(5,15), and P(5,10,15) was accomplished utilizing the route reported
by Goncalves et al. (26). This route provided these porphyrins in good yield. The
synthesis of P(5,10) was accomplished by the modification of a synthetic route reported
by Dogutan et al. (32). This new synthetic route provided for a more efficient means for
the synthesis of the P(5,10) analogue as compared to the Goncalves et al. route.
The binding of the new porphyrin ligands was compared to TMPyP4 for the
purpose of determining the effects of the ligand’s solvent accessible surface area (SASA),
charge, symmetry, and geometry on the thermodynamics of their interactions with G53

quadruplex DNA. The thermodynamic data given in Table 2.1 yield a couple of
surprises. The binding of the P(5,15) and to a lesser degree the P(5,10,15) compounds
seems to be tighter than expected, while the binding of the P(5,10) compound appears to
be weaker than expected. The Lewis group and others have previously suggested that the
two binding modes observed for the interaction of TMPyP4 with G-quadruplexes in
general, and more specifically with c- MYC, Bcl-2, and K-ras promoter sequence Gquadruplexes, are 1) an “end binding” mode, and 2) an “intercalation mode” (7, 8, 10).
The end-binding mode is generally accepted in the literature and is not controversial in
that stacking of the planar porphyrin ligand, TMPyP4, on a terminal G-tetrad is
consistent with simple π-π stacking and similar to guanine self-association. On the other
hand, the proposed intercalation mode is neither proven nor does it resemble simple selfassociation or the π-π stacking of the end binding interaction. However, the Lewis group
as well as others have published numerous studies that suggest that intercalation is
plausible, not only from the saturation stoichiometry which varies as the number of
stacked tetrads plus one (12), but also from the reduction in bound ligands from 4 to 2 as
the ligand becomes non-planar (15). Modeling studies show that TMPyP4 can intercalate
between the G-tetrads and that the structure of the G- quadruplex is not affected (33). All
of these results are also supported by CD data that indicate no change in the Gquadruplex CD spectrum on formation of the 4:1 TMPyP4/DNA complex. There is also
no induced CD signal for bound TMPyP4 until excess ligand is present, with excess
ligand more weakly bound to the exterior of the G- quadruplex, possibly in the grooves
(15). The thermodynamic signatures for these two modes are characteristic in that the
“end binding” mode is accompanied by a small favorable ΔH and a large favorable -TΔS
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term which drives the complex formation, while the “intercalation” mode is driven by a
large favorable ΔH and a negligible change in entropy (7). Using these same arguments,
the binding of the P(5,15) ligand is described as “intercalation” and the binding of the
P(5,10,15) ligand as “end binding”. In comparison to TMPyP4 which forms Gquadruplex complexes having a saturation stoichiometry of 4:1, the P(5,15) and
P(5,10,15) only form 2:1 complexes with the BCL-2 promoter sequence G-quadruplex.
The affinities reported in Table 3.1 for binding P(5,15) and P(5,10,15) to the
BCL-2 G-quadruplex are in general agreement with the affinities reported by Goncalves et
al. (26) for binding these same ligands to a human telomere G-quadruplex. In
comparison to this study’s ITC results for G-quadruplex complex formation with these
ligands, the SPR experiments of Goncalves et al. (26) yield a smaller ΔG° value for the
interaction of P(5,15) (-8.3 kcal/mol vs. -9.4 kcal/mol by ITC), a similar ΔG value for the
interaction of P(5,10,15) (-7.1 kcal/mol vs. -6.7 kcal/mol by ITC), and a smaller ΔG°
value for the interaction of TMPyP4 (-8.4 kcal/mol vs. -9.0 kcal/mol, the average ΔG° for
the mode 1 and mode 2 reactions as determined by ITC). All of these values are in good
agreement particularly since the Goncalves results are for binding to a human telomere Gquadruplex instead of the Bcl-2 G-quadruplex used in this study which exists as an
ensemble of at least three folded isomers. The biggest differences are that Goncalves et
al. (26) reports a significant affinity for binding the P(5,10) ligand to a human telomere
G-quadruplex, while complex formation between the P(5,10) ligand and the Bcl-2
promoter sequence G-quadruplex in either ITC or ESI-MS experiments was not observed
in this work. Additionally Goncalves et al. (26) failed to find the expected 4:1
stoichiometry for the TMPyP4 complex with the human telomere (34). The SPR study of
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Federici et al. reports two binding modes and a saturation stoichiometry of 4:1 for the
binding of TMPyP4 to the c-MYC promoter sequence G-quadruplex (35). Their two
reported affinities are: K1 ≈ 1.3×108 (ΔG = -11.0 kcal/mol) and K2 ≈ 7.7×105 (ΔG° = -8.0
kcal/mol). These are in excellent agreement with the previously reported values for the
interaction of TMPyP4 with the c-MYC, Bcl-2, and K-ras promoter sequence Gquadruplexes (7, 8, 10).
Whether the binding of P(5,15) is through end-binding, intercalation, or binding in
a G-quadruplex groove, its apparent high affinity points us in a new direction with respect
to designing G-quadruplex interactive ligands. In comparison to TMPyP4, the P(5,15)
ligand has a smaller SASA, and has a charge of only +2. However, P(5,15) binds to the
Bcl-2 G-quadruplex with almost the same affinity as TMPyP4, ΔG° = -9.4 kcal/mol vs. 10.4 kcal/mol for TMPyP4 (for binding the first two moles of TMPyP4). It also appears
to bind by the “intercalation mode” vs. the mode 1 interaction for TMPyP4 which has
been assigned to “end binding”. Perhaps even better G-quadruplex ligands could be
synthesized to take advantage of the trans (5,15) substitution pattern on the core
porphyrin, but with changes in the substituent charge or shape to produce stronger
interactions with either the G-tetrad(s), loops, or grooves of the G-quadruplex (36-38).
The weaker affinity of the P(5,10,15) ligand in comparison to TMPyP4 and its apparent
end binding are more difficult to explain. For example, why does the removal of a single
pyridinium substituent from TMPyP4 result in the loss of almost 3.5 kcal in the binding
energy? Perhaps the explanation is that the substituent pyridinium groups in TMPyP4 are
interacting with the loops, grooves and/or tail residues in the G-quadruplex and the loss of
one interaction is destabilizing. The Arya group has begun to exploit dual recognition
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with conjugated ligands incorporating both a planar moiety to base stack with an
aminoglycoside to bind in the quadruplex groove (36, 37). A better understanding of the
G-quadruplex interactions with model porphyrin ligands used in this study as well as
other new ligands will most certainly lead to better G-quadruplex stabilizing drugs.
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CHAPTER III
CALORIMETRIC AND SPECTROSCOPIC INVESTIGATIONS OF THE BINDING
OF METALLATED PORPHYRINS TO G-QUADRUPLEX DNA
Previously published in Biochimica et Biophysica Acta - General Subjects 2015,
1860, 902-909 and reproduced with permission
3.1

Abstract
The human telomere contains tandem repeat of (TTAGGG) capable of forming a

higher order DNA structure known as G-quadruplex. Porphyrin molecules such as
TMPyP4 bind and stabilize G-quadruplex structure. Isothermal titration calorimetry
(ITC), circular dichroism (CD), and mass spectrometry (ESI-MS) were used to
investigate the interactions between TMPyP4 and the cobalt(III), nickel(II), copper(II),
and zinc(II) complexes of TMPyP4 (e.g. Co-TMPyP4) and a model human telomere Gquadruplex (hTel22) at or near physiologic ionic strength ([Na+] or [K+] ≈ 0.15 M). The
apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4 all formed complexes having a saturation
stoichiometry of 4:1, moles of ligand per mole of DNA. Binding of apo-TMPyP4, NiTMPyP4, and Cu-TMPyP4 is described by a “four-independent-sites model”. The two
highest-affinity sites exhibit a Ka in the range of 108 to 1010 M−1 with the two loweraffinity sites exhibiting a Ka in the range of 104 to 105 M−1. Binding of Co-TMPyP4, and
Zn-TMPyP4, is best described by a “two-independent-sites model” in which only the
end-stacking binding mode is observed with a Ka in the range of 104 to 105 M−1. In the
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case of apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4, the thermodynamic signatures for
the two binding modes are consistent with an “end stacking” mechanism for the higher
affinity binding mode and an “intercalation” mechanism for the lower affinity binding
mode. In the case of Co-TMPyP4 and Zn-TMPyP4, both the lower affinity for the “endstacking” mode and the loss of the intercalative mode for forming the 2:1 complexes with
hTel22 are attributed to the preferred metal coordination geometry and the presence of
axial ligands. The preferred coordination geometry around the metal center strongly
influences the energetics of the interactions between the metallated-TMPyP4 and the
model human telomeric G-quadruplex.
3.2

Introduction
Human telomeric DNA offers an attractive therapeutic target in cancer research

(1). Telomerase, an enzyme that catalyzes telomeric extension in the 3′ overhang of
eukaryotic DNA, is expressed in a majority of cancer cells (2). Telomeric extension
inhibits the degradation of chromosomal DNA and thereby allows for replicative
immortality, whereas normal cells incur telomeric truncation of 50–200 bp with each
replicative cycle (3). Allosteric inhibition of telomerase activity would allow for
truncation without extension and therefore allow induction of senescence in malignant
cells (4).
The human telomere contains 5–15 kb pairs consisting of the repeat unit
(TTAGGG)n (3). These guanine-rich sequences are able to undergo conformational
changes to form a higher order DNA structure, consisting of a series of planar G-tetrads,
which are then stacked through π–π interactions to form a G-quadruplex (5). Gquadruplexes formed in the 3′-single strand overhang of the human telomere have been
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studied in cells (6, 7). Stabilization of this structure allows for the inhibition of
telomerase (4). Small molecules with selectivity and high affinity for G-quadruplex DNA
have been studied as potential therapeutic agents (8–13). Porphyrins are known to inhibit
telomerase with low cytotoxicity (8, 9). The interactions of the planar cationic porphyrin
TMPyP4 (meso-tetra (N-methyl-4-pyridyl)porphyrin tetrachloride, which exhibits
selectivity and high affinity for G-quadruplex DNA, have been studied extensively as a
model for drug stabilization of quadruplex DNA (8, 9, 14, 15).
The Lewis group has previously published several studies of TMPyP4 interactions
with G-quadruplex DNAs (13–17). It has been demonstrated that TMPyP4 binds in an n
+ 1 fashion, where n is the number of stacked tetrads in the quadruplex core. For
example, a G-quadruplex having three stacked G-tetrads, typically binds four moles of
TMPyP4 per mole of quadruplex DNA, with two moles of the TMPyP4 ligand binding
by a higher affinity mode, attributed to an end binding mechanism driven largely by a
favorable entropy contribution, and two moles binding by a lower affinity, intercalative
mode driven by favorable changes in enthalpy. Le et al. has also shown that planarity of
the ligand is needed for a complete saturation of the G-quadruplex, as TMPyP4 binds
with a 4:1 ratio while TMPyP3 and TMPyP2 only bind with 2:1 ratio (14). By
modulating the number of pyridyl substituents on the porphyrin, it was demonstrated that
charge, geometry, and symmetry also play important roles in the thermodynamics and
selectivity of binding porphyrins to G-quadruplex DNA (13). In this study, the
incorporation of four third row transition metals into the center of the porphyrin ring to
form metallated cationic porphyrins and its effects on binding were examined: CoTMPyP4, Ni-TMPyP4, Cu-TMPyP4, and Zn-TMPyP4. The goal was to understand how
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the presence of the metal, the additional positive charge, and the geometry of the metal
ion environment would affect the interactions of these metallated porphyrins with Gquadruplex DNA. Obviously the metallated porphyrins are not being developed as
potential drug compounds since the presence of the transition metals would be expected
to render these compounds to be either toxic or even carcinogenic. In effect, this study
was performed in an attempt to probe the effects of the metal ions on the binding
thermodynamics for the metallated porphyrin compounds in comparison to the parent
porphyrin, TMPyP4, and on the possible structures for their complexes with Gquadruplex DNA, again in comparison to the parent porphyrin, TMPyP4.
Isothermal titration calorimetry, in combination with ESI-MS and CD
spectroscopy, was used to characterize the interactions of the metal containing porphyrins
with a model human telomeric DNA sequence, hTel22. Although previous reports have
studied some aspects of these interactions, no one has examined these specific metallated
porphyrins using G-quadruplex DNA and isothermal titration calorimetry (18–20).
3.3

Materials and methods
The 22-mer oligonucleotide, hTel22, having the sequence 5′-A GGG TTA GGG

TTA GGG TTA GGG-3′, was obtained from Midland Oligos (Midland, TX). DNA stock
solutions were prepared by reconstituting the lyophilized oligonucleotide into its
respective phosphate buffer. The buffer concentrations consisted of 20 mM phosphate
and 150 mM total Na+ or K+ as the supporting electrolyte (the chloride form of the salt
was used), as well as 1 mM EDTA, at a pH of 7.0. Oligonucleotide was exhaustively
dialyzed (1000 MW cutoff membrane) against two changes of buffer solution (1 L, 24 h
each) at 4 °C. The DNA stock concentrations were verified using UV–Vis spectroscopy.
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DNA was annealed by quickly heating to 98 °C, holding for 10 min and then cooling to 5
°C over a 3 h period. The molar absorption coefficient was determined using a nearestneighbor method for single-stranded DNA (21).
Co-TMPyP4 (Co3+), Ni-TMPyP4, Cu-TMPyP4, Zn-TMPyP4, and apo-TMPyP4
were purchased as the chloride salts from Frontier Scientific (Logan, UT). The purity of
the commercial porphyrins was confirmed by thin layer chromatography (TLC), UV–Vis
and NMR spectroscopy as provided by the company. Porphyrin samples were prepared
by careful weighing and dissolving in the final dialysate buffer for respective
experiments. Concentrations of the metallated porphyrin ligand solutions were
determined by weight as the published extinctions coefficients were unreliable for the
metallated porphyrins in the phosphate buffers used in this study.
ESI-MS experiments of hTel22 porphyrin complexes were carried out on a
Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in negative
ion mode. All experiments were performed in 50 mM ammonium acetate buffer (pH 7.0)
containing 20% HPLC grade methanol. The hTel 22-mer G-quadruplex sample was
dialyzed against three changes of buffer, 24 h each, at 4 °C. Stock solutions of the
porphyrin were prepared in the final dialysate buffer. The ESI-MS samples were prepared
by stepwise, slow addition of porphyrin into hTel22 solution. The MS capillary voltage
was set to +3500 V, dry N2 gas flow was adjusted to 0.5 L/min at 110 °C, and the Gquadruplex/porphyrin samples were directly infused into the MS by using a kD Scientific
syringe pump set to a flow rate of 200 μL/h. Data processing was performed using Bruker
Daltonics Data Analysis program.
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CD experiments were performed with an Olis DSM-20 spectropolarimeter
(Bogart, GA). All measurements were performed at 25 °C using a 1 cm quartz cuvette
and covering a spectral range of 220–320 nm.
ITC experiments were performed using a VP-ITC calorimeter (GE Healthcare). A
typical ITC experiment consisted of either 28 (10 μL) or 56 (5 μL) injections of a dilute
porphyrin solution into a dilute hTel22 DNA solution. Blank titrations were determined
by injecting porphyrin into buffer solution. These dilution heats were subtracted from the
ITC data for the DNA-porphyrin titrations, yielding dilution corrected heats. Corrected
ITC titrations were then fit with a nonlinear regression algorithm using CHASM, a data
analysis program developed in the Lewis laboratory (22).
3.4

Results
The ESI mass spectra for solutions containing mixtures of metallated-TMPyP4

complexed to hTel22 are shown in Figure 3.1. In comparison to the ESI mass spectra for
the solution containing only hTel22 (11), ESI mass spectra for mixture solutions of
metallated-TMPyP4/hTel22 did not contain any m/z peaks of 1740.5 or 2321.0, which
correspond to the −4 and −3 unbound hTel22 species. In all four cases, the ESI mass
spectra shown in Figure 3.1 provide evidence of complex formation between hTel22 and
metallated-TMPyP4. In contrast to the ESI mass spectrum for a solution containing apoTMPyP4/hTel22 in which several m/z peaks corresponding to the highest 4:1 saturation
stoichiometry could be observed, the ESI mass spectra for solutions containing
metallated-TMPyP4/hTel22 only provide evidence for the formation of 2:1 complexes for
the Co- and Zn-TMPyP4 ligands and only provide evidence for the formation of the 3:1
complexes of the Ni- and Cu-TMPyP4 ligands. Furthermore, the natural isotopes of the
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metal (Co, Ni, Cu, and Zn) result in the ESI mass spectra being more complex than
observed for apo-TMPyP4. However, the isotopic distribution patterns observed in the
ESI mass spectra matched with those simulated by using the Bruker Daltonics Data
Analysis program.
Circular dichroism spectropolarimetry was used to investigate the effect of
titrating apo-TMPyP4 and metallated-TMPyP4 into hTel22 G-quadruplex DNA. The CD
spectra for the titrations of the apo-TMPyP4 and metallated-TMPyP4 into hTel22 Gquadruplex in 150 mM Na+ are illustrated in Figure 3.2. The CD spectra of the hTel22 Gquadruplex, in the absence of any ligand, exhibited characteristic peaks at 245 nm and
295 nm as well as a trough at 265 nm (23). Additions of apo-TMPyP4 into hTel22
resulted in significant attenuation in the CD signal at 265 nm and to a lesser extent in the
CD signal at 295 nm. The titrations of metallated-TMPyP4 exhibited differential effects
on the CD signals of the hTel22 G-quadruplex depending on the metal center in the
metallated-TMPyP4. Titrations of Co- and Zn-TMPyP4 exhibited negligible effects on
the CD signal of hTel22 up to 6 equivalence of the ligands. Addition of Ni- and CuTMPyP4, however, resulted in significant attenuation in the CD signals at both 265 nm
and 295 nm. These signal attenuations, caused by addition of Ni- and Cu-TMPyP4, are
even more pronounced than the signal attenuations observed for the additions of the apoTMPyP4 into hTel22 at the same molar ratio of ligand/DNA. Notably, the signal
attenuations were also accompanied by shifts in the wavelength at both 265 nm and 295
nm.
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Figure 3.1

Electrospray ionization mass spectra for solutions containing hTel22 G-quadruplex DNA and excess amounts CoTMPyP4 (panel A), Ni-TMPyP4 (panel B), Cu-TMPyP4 (panel C), and Zn-TMPyP4 (panel D).

Similar titration experiments were conducted for additions of apo- and metallatedTMPyP4 into hTel22 in potassium buffer. The CD titrations performed in 150 mM K+
phosphate buffer are shown in Figure 3.3. In contrast to CD signals for the hTel22
observed under Na+ conditions, the CD signals for the hTel22 observed under K+
conditions are clearly distinctive with a characteristic shoulder at 265 nm and a peak at
295 nm (23). Additions of apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4 into K+ form
hTel22 all resulted in significant attenuation in the CD signal at 295 nm. Similar to CD
titrations performed under Na+ conditions, the addition of Co- and Zn-TMPyP4 had
minimal effect on the CD signals of K+ form hTel22 up to 6 equivalence of the ligands.
The signal attenuations near 295 nm were also accompanied by red shifts.

Figure 3.2

CD titration data for complexation of the hTel22 G-quadruplex with apoand metallated-TMPyP4 in 150 mM Na+ BPES buffer.

CD spectra of the Na+ salt hTel22 G-quadruplex are represented as (▬) while the spectra for the
titrations of apo- and metallated-TMPyP4 into hTel22 are shown in colors. The CD titration data
were collected at 1:1, 2:1, 3:1, 4:1, and 6:1 ratios of ligand per DNA and were corrected for the
signal of ligands at the corresponding ratios. Arrows indicate the shifts at the characteristic
wavelengths for Na+ hTel22.
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CD spectra are difficult to interpret and the subtle changes in the 295 region are
only noted here to indicate that the strongly binding compounds, TMPyP4, Ni-TMPyP4,
and Cu-TMPyP4 are influencing the structure of the hTel22 G-quadruplex. The important
point is that there are no significant changes in the G-quadruplex signature peaks in the
CD titrations employing the more weakly interacting Co and Zn porphyrins. Explaining
the small blue and red shifts observed in the 295 nm region for both the Na+ and K+
hTel22 G-quadruplexes when titrated with TMPyP4, Ni-TMPyP4, or Cu-TMPyP4 is
beyond the scope of this manuscript.

Figure 3.3

CD titration data for complexation of the hTel22 G-quadruplex with apo
and metallated-TMPyP4 in 150 mM K+ BPES buffer.

CD spectra of the Na+ salt hTel22 G-quadruplex are represented as (▬) while the spectra for the
titrations of apo and metallated-TMPyP4 into hTel22 are shown in colors. The CD titration data
were collected at 1:1, 2:1, 3:1, 4:1, and 6:1 ratios of ligand per DNA and were corrected for the
signal of ligands at the corresponding ratios. Arrows indicate the shifts at the characteristic
wavelength for K+ hTel22
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To further investigate the interactions between hTel22 G-quadruplex with both
the apo-TMPyP4 and metallated-TMPyP4, a series of ITC experiments in two different
buffer conditions was performed: 150 mM Na+ and 150 mM K+. As shown in Figures 4.4
and 4.5, the titration experiments of TMPyP4 (both apo- and metallated-) into hTel22 Gquadruplex are more complex than the TMPyP4 titrations previously reported for the
addition of TMPyP4 to oncogene promoter sequence G-quadruplexes for c-MYC, BCl-2
and K-ras (14–17). Figure 3.4 shows the titration data of the apo- and metallatedTMPyP4 into hTel22 G-quadruplex in 150 mM Na+ BPES buffer. The titrations shown in
Figure 3.4 have been corrected for the heats of dilution of the ligand (apo- and
metallated-TMPyP4) into buffer. The titration data for apo-TMPyP4, Ni-TMPyP4, and
Cu-TMPyP4, shown in the left panel of Figure 3.4, could not be adequately analyzed
using the two-binding site model provided by the ITC manufacturer; instead they were fit
to a three-event model using CHASM ITC data analysis software (22). However, the
titration data for Co-TMPyP4 and Zn-TMPyP4, shown on the right panel of Figure 3.4,
were adequately fit to a simple single binding event either by using the commercial
software (Origin) or software developed in the Lewis laboratory (CHASM).
The titration data of the apo- and metallated-TMPyP4 into hTel22 G-quadruplex
in 150 mM K+ BPES buffer are shown in Figure 3.5. The titrations shown in Figure 3.5
have been corrected for the heats of dilution of the ligand (apo- or metallated-TMPyP4)
into buffer. Similar to the titration experiments performed in Na+ buffer, titration data of
the apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4, shown in the left panel of Figure 3.5,
were fit to a three-event model using CHASM while the titration data for Co-TMPyP4
and Zn-TMPyP4, shown on the right panel of Figure 3.5, were fit to a single binding
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event, Co, or to a two binding event model, Zn. Notably, for ITC experiments performed
in both potassium and sodium conditions, the titrations of apo- TMPyP4, Cu-TMPyP4,
and Ni-TMPyP4 into hTel22 exhibit saturation stoichiometries occurring near a molar
ratio of 4:1. On the other hand, titrations of Co-TMPyP4 and Zn-TMPyP4 into hTel 22mer exhibit a 2:1 saturation stoichiometry.

Figure 3.4

Typical nonlinear regression fits for the titration of apo (○) andmetallatedTMPyP4 into hTel22 G-quadruplex in 150 mM K+ BPES buffer.

Titration data ofmetallated-TMPyP4 are represented as following: Co-TMPyP4(■), NiTMPyP4 (▲), Cu-TMPyP4 (▼), and Zn-TMPyP4 (●). The titration data shown on the
left panel were fit to a three-event model and the titration data shown on the right panel
were fit to a single-event model. The non-linear best fits are shown in red.

Table 3.1

Thermodynamic parameters obtained from ITC experiments for the
formation of the apo-TMPyP4 complexes with hTel22 in Na+ and K+ buffer
conditions.
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Table 3.2

3.5

Thermodynamic parameters obtained from ITC experiments for the
formation of metallated-TMPyP4 complexes with hTel22 G-quadruplex in
150 mM Na+ buffer conditions.

Discussion
The Lewis group has recently reported on the use of ESI-MS to reveal the

complex species formed and the saturation stoichiometry for ligand/DNA complexes (11,
13, 14, 24, 25). Similar to the mass spectrometry data obtained for TMPyP4 complexed
with a 27-mer Bcl-2 promoter sequence G-quadruplex, ESI mass spectra indicated that
the planar cationic porphyrin TMPyP4 exhibited a 4:1 saturation stoichiometry with
human telomeric G-quadruplex hTel22. The absence of any m/z peaks corresponding to
free DNA in the ESI mass spectrum for a solution containing apo-TMPyP4 and hTel22,
is indicative of the high affinity exhibited by the TMPyP4 toward the hTel22 Gquadruplex. Similarly, there were no m/z peaks corresponding to the free DNA in the ESI
mass spectra for solutions containing any of the four different metallated-TMPyP4
ligands and hTel22 G-quadruplex DNA. This suggests that all four metallated-TMPyP4
ligands bind to hTel22 with moderate to high affinity under the conditions of these
experiments. However, in contrast to the ESI-MS experiments performed with the apoTMPyP4, m/z peaks corresponding to ligand/DNA ratios greater than 3:1 for the Ni, Cu,
and Zn compounds or greater than 2:1 for the Co-TMPyP4 compound, were not
74

observed. Furthermore, the m/z peaks observed in the mass spectrum for the apoTMPyP4/hTel22 complex are much sharper than those observed for the metallatedTMPyP4/hTel22 complexes.
Even though Co-TMPyP4 only exhibits a maximum 2:1 stoichiometry with
hTel22, while the remaining Cu-TMPyP4, Ni-TMPyP4, and Zn-TMPyP4 exhibited a
maximum of 3:1 stoichiometry, these ratios are in poor agreement with the ITC endpoints
that indicate saturation stoichiometries of 4:1 for the apo-TMPyP4 (confirmed by ESIMS), and 4:1 for the Ni and Cu TMPyP4 compounds (where the ESI-MS data show
maximum mole ratios of 3:1). An explanation for these differences is that the 4:1
metallated porphyrin complexes have lower solubility and precipitate in the solutions
prepared for the ESI-MS experiments. The very small amounts of the 3:1 ZnTMPyP4/hTel22 complex observed in the ESI-MS spectrum may be the result of some
nonspecific ligand binding whereas the 2:1 mol ratio species observed in both the CoTMPyP4/hTel22 and Zn-TMPyP4/hTel22 solutions are in agreement with the ITC
endpoints. We have elected to use the ITC stoichiometries with some caution since they
are not universally confirmed by the ESI-MS experiments.
The CD titration experiments revealed useful insights into the type of interactions
that a particular ligand may impose on the structure of the DNA. The change in signal of
the G-quadruplex was observed to determine how binding of a given metallated-TMPyP4
may alter the structure of the hTel22 G-quadruplex. Several conclusions can be drawn
from the CD titration experiments performed under both Na+ and K+ conditions. First, the
interactions of the apo-TMPyP4 with the hTel22 G-quadruplex proceed with only slight
modification of the telomeric G-quadruplex solution structure. Secondly, the interactions
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of both Co-TMPyP4 and Zn-TMPyP4 with the hTel22 G-quadruplex proceed through a
mechanism that results in essentially no change in the structure of the hTel22 Gquadruplex. Thirdly, the CD titration experiments suggest that the interactions of both NiTMPyP4 and Cu-TMPyP4 with the hTel22 G-quadruplex are most similar to the
interactions of apo-TMPyP4 with the hTel22 G-quadruplex, albeit exhibiting a greater
change in the hTel22 G-quadruplex solution structure.
The Lewis laboratory’s previous work has documented that the interactions
between the planar cationic porphyrin, TMPyP4, and any G-quadruplex DNA, having
three stacks of G-tetrads (e.g. 27-mer Bcl-2, 27-mer c-myc, and 30-mer K-ras), can
typically be described by a model which includes two different binding modes, with each
binding mode having two identical binding sites. The higher affinity binding mode is
predominantly driven by the change in entropy while the lower affinity binding mode is
driven by the change in enthalpy (14–17). The high affinity binding site has been
attributed to “end-stacking” of the planar porphyrin to the top or bottom of the Gquadruplex core while the lower affinity site has been attributed to intercalation of the
porphyrin between adjacent G-tetrads in the G-quadruplex core (14).
This study was initially designed to determine/understand how the preferred
coordination geometry around the metal center, in a series of metallated-TMPyP4
ligands, might influence the energetics of the interactions between the metallatedTMPyP4 ligands and model 22-mer human telomeric G-quadruplex constructs.
Specifically, the interactions between the metallated-TMPyP4 and hTel22 would be
compared to the interactions between apo-TMPyP4 and hTel22. However, the
thermograms for the titration of apo-TMPyP4 into hTel22, in either Na+ or K+ solutions,
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are more complicated than expected. The presence of an additional event in the early part
of the titrations, specifically between 0 and 1 mol ratio of TMPyP4 to DNA, indicates
that the previously proposed model (4 sites and two modes) for the interactions of
TMPyP4 with for example the c-MYC promoter sequence G-quadruplex is not adequate
to describe the interactions between apo-TMPyP4 and hTel22. The additional reaction in
the early part of the hTel22 titrations required us to use ITC analysis software developed
in the Lewis laboratory to fit these titration data to a three-event model. The
thermodynamic parameters for the interactions between apo-TMPyP4 and hTel22 in
either Na+ or K+ solutions are given in Table 3.1.
Given the drastic difference in structural complexity between the K+ form and the
Na+ form of telomeric G-quadruplex, as indicated by the CD experiments, the
interactions between apo- TMPyP4 and hTel22 would be expected to be accordingly
different. These differences are most apparent in the first reaction occurring in the early
part of the titrations, i.e. the binding affinity exhibited by apo-TMPyP4 toward hTel22 in
K+ form is almost an order of magnitude higher than for the Na+ form. This difference in
binding affinity and the corresponding binding free energy (ΔΔG1 = −1.3 kcal/mol) of the
first reaction is the result of the compensating effect between the enthalpy and entropy
change terms. For the Na+ hTel22 G-quadruplex, the first reaction is predominantly
driven by the enthalpy change, while the first reaction for the K+ hTel22 G-quadruplex is
mainly driven by a change in entropy. Beyond the differences in the energetic profiles for
the first reaction, the second and third reactions exhibit some similarities in their binding
energetics: e.g. the second reaction is approximately two to three orders of magnitude
greater in terms of binding affinity in comparison to the third reaction (or ΔΔG2–3 = ΔG2 −
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ΔG3 of approximately −3 to −4 kcal/mol). Entropy changes provide the driving force for
the second reaction while enthalpy changes drive the third reaction.
Even though we can only speculate what the first reaction may be in these hTel22
titrations, the second and third reactions are consistent (at least in terms of their
thermodynamic profiles) with the previous model for binding TMPyP4 to G-quadruplex
DNA. In other words, the second reaction is likely an “end-stacking” interaction to bind
the second mole of TMPyP4 to form the (TMPyP4)2(hTel22) complex species and the
third reaction is attributed to the “intercalation” of two additional moles of TMPyP4 to
form the (TMPyP4)4(hTel22) complex species. The additional heat in the early part of the
apo-TMPyP4 (or the metallated-TMPyP4) titration of hTel22 is unique to titrations of the
human telomeric G-quadruplex.
There are two plausible explanations for the extra heat and apparent increased
affinity for binding the first mole of TMPyP4 to hTel22. One explanation would be that
the hTel22 G-quadruplex has a solution structure wherein one end of the G-quadruplex
core binds TMPyP4 much more tightly than the other end of the G-quadruplex core. A
second and more likely explanation is that there is a ligand induced structural
reorganization of the hTel22 G-quadruplex that accompanies binding of the first mole of
TMPyP4. The second explanation finds support in the fact that hTel22 G-quadruplex is
known to exhibit structural complexity in the form of multiple foldamers in dynamic
equilibrium. For example, Phan and Patel have published NMR studies which suggested
that the two-repeat human telomeric sequence d(TAGGGTTAGGGT) can form both
parallel form and anti-parallel folded structures in 100 mM K+ and the two foldamers are
in dynamic equilibrium at room temperature (26). The first reaction in the titration of
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apo-TMPyP4 to hTel22 G-quadruplex can be described as the apo-TMPyP4 binding
simultaneously to multiple hTel22 foldamers; this binding is coupled with some ligandinduced refolding of hTel22. It is conceivable that apo-TMPyP4 exhibits a higher affinity
toward a specific hTel22 G-quadruplex topology and that this conformational selection
shifts the dynamic equilibrium between the foldamers to a new equilibrium populated by
the most thermodynamically favored apo-TMPyP4/hTel22 complex.
The titration data for the interactions between hTel22 and metallated-TMPyP4
have also been analyzed using the appropriate models. The thermodynamic parameters
for the interactions between the metallated-TMPyP4 and hTel22, in solutions containing
either Na+ or K+, are shown in Tables 3.2 and 3.3.
As previously noted in the Results section, the thermograms for titration of either
Co-TMPyP4 or Zn-TMPyP4 to hTel22 are very different from the titration experiments
of apo-TMPyP4 to hTel22. Not only do these thermograms mostly lack the initial early
reaction between 0 and 1 M ratio, but these thermograms also do not exhibit the classical
“check mark” pattern as previously observed for c-MYC, Bcl-2 or K-ras G-quadruplex.
Instead, the titrations of either Co-TMPyP4 or Zn-TMPyP4 to hTel22 exhibit a simple
sigmoidal curve. The ITC experiments provide strong evidence that the presence of a
metal in the center of the metallated-TMPyP4 plays a significant role in the interactions
between these porphyrins and hTel22 G-quadruplex.
Interactions between Co-TMPyP4 and hTel22 exhibit the lowest binding affinity
among the series of metallated-TMPyP4 under both Na+ and K+ conditions. These
binding affinities of Co-TMPyP4 to hTel22 are most comparable to the binding affinities
determined for the third reaction in the titration of apo-TMPyP4 to hTel22. The enthalpic
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and entropic contributions for binding of Co-TMPyP4 to hTel22, however, are more
consistent with the second reaction in the titration of apo-TMPyP4 to hTel22. Based on
the observation from the CD titration experiments in which subsequent addition of the
Co-TMPyP4 resulted in almost no change in the CD signal of the hTel22 and the binding
energetics obtained from ITC experiments, the binding of Co-TMPyP4 to hTel22 likely
occurs via an exterior or “end-stacking” like mechanism. Except for a coordinating cobalt
at the center of the porphyrin ring, Co-TMPyP4 is structurally similar to the apoTMPyP4. The geometry and ligand environment around the cobalt center in Co-TMPyP4
must therefore account for the significant reduction in binding affinity and a complete
loss of the “intercalative” mode as observed for binding of apo-TMPyP4 to hTel22.
Zn-TMPyP4 exhibits some similarity to Co-TMPyP4 in terms of its binding to
hTel22, although its binding affinities toward hTel22 are slightly higher than CoTMPyP4 under both Na+ and K+ conditions. The interactions of Zn-TMPyP4 to hTel22 in
Na+ conditions can be modeled via a single binding event which is predominantly driven
by enthalpy change. The interactions of Zn-TMPyP4 to hTel22 in K+ conditions,
however, had to be modeled by two overlapping binding processes with the higher
affinity binding driven by enthalpy change while the lower affinity binding is driven by
entropy change. Although the interaction between Zn-TMPyP4 and hTel22 in K+
conditions can be described via a two binding-process, the enthalpic and entropic
contributions are not consistent with a ligand binding proceeding through “end-stacking”
followed by “intercalation” mechanism. Furthermore, the CD titration experiment of ZnTMPyP4 to hTel22 also ruled out the possibility of the “intercalation” mechanism during
which some attenuation of the CD signal are often observed at characteristic wavelengths
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for hTel22 G-quadruplex. A plausible explanation for two binding events, as observed for
the interactions of Zn-TMPyP4 to hTel22 in K+ salt, may be the preferential binding of
Zn-TMPyP4 toward one hTel22 foldamer over the others.
Ni-TMPyP4 and Cu-TMPyP4 exhibit many similarities in comparison to apoTMPyP4 with respect to their binding to hTel22 under both Na+ and K+ conditions. First,
their titration experiments all contain the first reaction in the early part of the titrations
(between 0 and 1 mol ratio) followed by the “checkmark” pattern. Secondly, the entropic
contribution dominates the second reaction while the enthalpic contribution is the main
driving force for the third reaction. These thermodynamic signatures, in combination with
CD titration experiments, are in very good agreement with a process in which formation
of the “end-stacking” complex is followed by the “intercalative” complex. The difference
arises from comparing the thermodynamics of the first reaction in Na+ buffer versus the
K+ buffer. The enthalpic change is the main driving force for the first reaction of binding
either Ni- TMPyP4 or Cu-TMPyP4 to hTel22 G-quadruplex in Na+ buffer. The complete
opposite is observed for the first reaction of binding either Ni-TMPyP4 or Cu-TMPyP4 to
hTel22 G-quadruplex in K+ buffer in which the entropy change is the main driving force.
This trend is very similar to thermodynamics of the first reaction during the binding of
apo-TMPyP4 to hTel22 (see Table 3.1). With the original speculation that the first
reaction is initially ligand binding coupled with a conformational reorganization of the
hTel22, the difference in the thermodynamics of the first reaction, as observed in the Na+
salt versus the K+ salt, must arise from the difference in the hTel22 pool of foldamers in
Na+ vs. K+ containing solutions.
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The question to be asked is why Ni-TMPyP4 or Cu-TMPyP4 behave similarly to
apo-TMPyP4 with respect to their interactions with hTel22 while Co-TMPyP4 or ZnTMPyP4 behave very differently. These differences must be due to the metal ion and the
coordination geometry and ligand environment around the metal center in metallatedTMPyP4, in comparison to apo-TMPyP4. Zn-TMPyP4 has been reported to have two
axial ligands coordinating in an octahedral environment, (27) thereby hindering its ability
to effectively form a π–π stacking with the G-tetrads, resulting a lower binding affinity
toward hTel22, as well as completely inhibiting the formation of the intercalative
complex. Ni-TMPyP4 is in a very fast equilibrium between the unbound (4 coordinate,
square planar) and diaqua (2 × H2O, 6 coordinate, octahedral) complexes (28, 29). This
very fast equilibrium can be re-established to favor the unbound square planar geometry
of Ni-TMPyP4, which is capable of forming “end-stack” as well as “intercalative”
complexes with hTel22 G-quadruplex. Cu-TMPyP4 has no obstacle for binding from
axial ligands as its preferred coordination geometry is square planar (28). The higher
affinity for Cu-TMPyP4 toward hTel22 in comparison to the apo-TMPyP4 may also
come from additional orbital interactions between the metal ion and the oxygen atoms
from the guanines of the G-tetrads. Lastly, Zn-TMPyP4 has strongly bound axial water in
a square pyramidal environment, causing a decrease in affinity for end-stacking and
inhibiting the intercalative mode (30).
This study employed isothermal titration calorimetry, in combination with ESIMS and CD spectroscopy, to investigate the interactions between a apo-TMPyP4 and a
series of metallated-TMPyP4 compounds (Co3+, Ni2+, Cu2+, and Zn2+) and the human
telomeric G-quadruplex. The interactions between apo-TMPyP4 and the hTel22 alone,
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measured by ITC, are more complex than originally expected. The additional complexity
seems to be explained on the basis of the topological diversity presented by the hTel22
G-quadruplex. The differences in the binding of the M-TMPyP4 ligands seem to lend
additional support for the two binding mode model previously proposed. The two mode
model incorporating both “end-stacking” and “intercalative” binding mechanisms seems
to explain the differences in the interactions of the apo-TMPyP4, Ni-TMPyP4, and CuTMPyP4 ligands with hTel22 G-quadruplex DNA and the interactions of the CoTMPyP4 or Zn-TMPyP4 ligands with the hTel22 G-quadruplex construct. In addition,
the higher affinity exhibited by Cu-TMPyP4 (over apo-TMPyP4) may provide a basis for
the development of better G-quadruplex interactive ligands.
This study provide lessons regarding both the utility and the limitations of the ITC
technique for the measurement of the thermodynamic parameters, K (or ΔG), ΔH, −TΔS,
and n, for a weak (non-covalent) interaction of interest. The power of the
microcalorimetry technique lies in the fact that most reactions proceed with either the
evolution or the absorption of heat (i.e. the microcalorimeter is a universal detector). The
limitation of the microcalorimetry technique is that other techniques must often be used
in combination with the microcalorimetry technique in order to identify the origin of the
measured heat effects. Another point to be made from the present study is that the results
of an ITC study will almost always be model dependent in that a thermodynamic model
must be used to deconvolute the observed thermograms into a set of best fit
thermodynamic parameters for the model reactions.
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CHAPTER IV
THE THERMODYNAMIC EFFECTS OF LIGAND STRUCTURE ON THE
MOLECULAR RECOGNITION OF RUTHENIUM COMPLEXES
WITH B-DNA
4.1

Abstract
Ruthenium(II) complexes have garnered increasing interest over the last 20 years

including investigations into their properties as chemosensors and chemotherapeutic
agents. Some polyheterocyclic ruthenium compounds have shown less toxicity and are
able to overcome the resistance seen with platinum drugs. Due to the hypoxic
environment present in a broad range of tumors versus normoxic cells,
[Ru(phen)2(tatpp)]2+ (MP) is able to abstract a hydrogen atom from a DNA backbone
deoxyribose, resulting in DNA cleavage. The binding mode of mononuclear
[Ru(phen)3]2+ (Rp3) has been thoroughly examined and is reported to bind via minor
groove association while [Ru(phen)2(dppz)]2+ (Rp2d) is able to intercalate. Le et al.
recently reported on the binding of binuclear [(phen)2Ru(tatpp)Ru(phen)2]4+ (P4+) which
had a greater binding affinity for duplex DNA than Rp3 and bound through an
intercalative mode. To further understand the role of the intercalative ligand substituent,
Ru2+ compounds were examined, starting at Rp3 and building to P4+, and the primary
binding events for all ligands were entropically driven with either low or unfavorable
enthalpic contributions. The binding affinities to duplex DNA followed as Rp3 < P4+ <
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Rp2d < MP. A second binding mode, two orders of magnitude weaker than the first,
was seen for Rp2d.
4.2

Introduction
Ruthenium anticancer drugs have attracted an increasing interest in the last 20

years including examination in clinical trials and compared to platinum drugs, the
complexes based on ruthenium are often identified as less toxic and capable of
overcoming the resistance induced by platinum drugs in cancer cells (1-4). Ruthenium
complexes have shown selective activation to more reactive species by the reducing
environment of solid tumors as compared to healthy tissues (5-7). Numerous studies
have noted the important aspects of the photophysical properties of these ruthenium
complexes (8-12). 1-5 2-6
Ruthenium(II) containing drug [Ru(phen)2(tatpp)]2+ (MP) showed promising
results in a 60 day tumor regression trial that examined the growth of solid tumors in
H358 bearing mice treated with the Δ enantiomer of MP. Results of this study included a
greater than doubled subject survival time and a marked decrease of 83% less tumor
growth compared to the untreated control (7). Additional studies measuring the acute
toxicity of MP in animals showed that low toxicity existed at the doses needed in
therapeutic treatment.
Reports furthering the understanding of the mode of action of these drugs have
indicated that its primary function arises through H-atom extraction in a deoxyribose by a
carbon radical on the tatpp ligand, causing DNA cleavage (7, 13). Dioxygen, present in
only low levels in hypoxic tumor cells compared to normoxic cells, is able to quench the
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radical, leading to selective cleavage of DNA in malignant cells versus healthy, normally
functioning cells, as seen with the non-reactivity in healthy tissues (7, 13).
Prior publications by the Lewis group and others have examined the
thermodynamic parameters involved in the binding of ruthenium(II) containing structures
(14). Reports by Chaires’ group examined the binding relationship of mononuclear
ruthenium(II) complexes and proposed that [Ru(phen)3]2+ (Rp3) bound through a nonintercalative mechanism, but that by building upon one of the phenanthroline groups,
forming [Ru(phen)2(dppz)]2+ (Rp2d), intercalation was possible and favored. Le et al.
previously reported that [(phen)2Ru(tatpp)Ru(phen)2]4+ (P4+) bound to DNA through an
intercalative binding mode that took advantage of the dynamic “breathing” exhibited by
duplex DNA. This present work set out to examine how increasing the size of the
modified phenanthroline would affect the binding of these ruthenium(II) containing
complexes using ITC to extract the entirety of the binding thermodynamics and to
supplement those with CD experiments to validate the changes in structure. To our
knowledge, no other groups have published studies examining the structure function
relationship of these increasingly substituted heterocycle-containing [Ru(L)(phen)2]2+
analogs.
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Figure 4.1

Structures of the Ru2+ compounds used in this study.

P=[(phen)2Ru(tatpp)Ru(phen)2]4+, MP=[Ru(phen)2(tatpp)]2+, Rp2d=[Ru(phen)2(dppz)]2+,
Rp3=[Ru(phen)3]2+

4.3

Material and methods
The target DNA was 25 base pair dsDNA (25bp duplex) (5′-ATC AAG CTA

CGG TCT GTG AGC AAG T-3′/5′-ACT TGC TCA CAG ACC GTA GCT TGA T-3′)
purchased from Midland Certified Reagent Co. as the RP grade and used without further
purification. The 25bp duplex was exhaustively dialyzed against 80 mM Na+ BPES
buffer (50 mM NaCl; 10 mM Na2HPO4; 10 mM NaH2PO4; 1 mM EDTA) at pH = 7.0
and annealed by heating to 95 oC and holding for 10 minutes followed by cooling to 5 °C
at a rate of 0.5 °C/min.
Ligands were dissolved in the final dialysate buffer and their concentrations
calculated from mass of ligand used MP = 1018.9 g/mol; [Ru(phen)2dppz]2+ (Rp2d) =
814.69 g/mol; [Ru(phen)3]2+ (Rp3) = 712.59 g/mol). Working solutions were made fresh
prior to experiments by dissolution of the weighed solid into the final dialysate and kept
at RT in a drawer away from ambient light. [Ru(phen)2dppz]2+ required substantial heat
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and sonication to dissolve completely into the buffer systems. MP required initial heat
and sonication to dissolve. [Ru(phen)3]2+ readily dissolved in the chosen buffers.
ITC experiments were performed using a Microcal VP-ITC (Malvern) at 25 oC. A
typical experiment involved injection of 28 aliquots of dilute ligand (nominally 120 to
850 μM) into the calorimeter cell containing 1.45 ml of 10 μM DNA. Injection volumes
were 10 μl and injections were made at 200 second intervals. The ITC thermograms were
corrected for titrate and titrant dilution effects by performing the appropriate blank
experiments and correcting the observed heats by subtracting the heats of dilution.
Corrected ITC titrations were fit with a nonlinear regression algorithm using CHASM, an
ITC data analysis program developed in the Lewis laboratory (15).
CD experiments were performed using an Olis DSM-20 spectropolarimeter
(Bogart, GA). Typical experiments involved the titration of ligand into a DNA sample
with a nominal A260 = ~1. Corrections were made by subtracting the signal of ligand
titrated into buffer from its respective sample and converting to molar ellipticity.
ESI-MS experiments on 7 base pair hairpin (7bpHP) and the (Ligand·7bpHP)
complex were carried out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition
was set to operate in negative ion mode. All experiments were performed in 50 mM
ammonium acetate buffer (pH = 7.0) containing 20% HPLC grade methanol. The 7bpHP
sample was prepared at a concentration of approximately 40 μM in the ammonium
acetate buffer and was exhaustively dialyzed at 4 °C. Stock solutions of the ligands were
prepared in the same final dialysate buffer. The ESI-MS samples were prepared by
mixing the hairpin DNA and ligand stock solutions to yield a mixture containing 4
equivalents of ligand molecules per molecule of hairpin DNA. The MS capillary voltage
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was set to +4000 V, dry N2 gas flow was adjusted to 4 L/min at 190 °C, and the sample
was directly infused into the MS by using a kD Scientific syringe pump set to a flow rate
of 180 μL/h. Data processing was performed by using the Bruker Daltonics Data
Analysis program.
Molecular modeling was performed by Clinton G. Mikek who used Discovery
Studio 3.1. DNA-ligand molecules were drawn using the internal build functions,
calculated with the CHARMm force field, and minimized with an implicit solvent model
dielectric constant of 80.
4.4

Results
Le et al. previously reported on P4+ binding to B-DNA with an average affinity of

~ 4 × 105 M−1 through an entropically driven intercalative mechanism (14). This work
seeks to present data on structural derivatives of this parent compound. MP, Rp2d, and
Rp3 are structurally similar to the original P4+ with the exception of truncation of the
structure to form a shorter tatpp, dppz, or phen protrusion from the [Ru(Phen)2]2+ base
and exclusion of the second Ru2+ in the case of MP.
Table 4.1 summarizes the ITC data collected from the titration of concentrated
ligand into a dilute sample of DNA in Na+ BPES buffer, while Table B.1 repeats this in
Tris buffer. ITC derived data for the binding of MP to DNA show an n value which is
equal to the 12-13 sites available by observation of the nearest neighbor exclusion for 25
bp duplex. This was a racemic mixture of MP containing Δ and Λ molecules.
Experiments with the enantiomerically pure MP would be worthwhile to ensure
conformity across the enantiomers. MP binding is characterized in this study by a small
enthalpic penalty against a larger entropic driving force resulting in a value for ΔG of -9.1
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kcal/mol. The profile for MP binding to 25 bp duplex DNA is similar to that for binding
of P4+ in which the previously reported formation of P4+·DNA complexes were
entropically driven (−TΔS = −9.7 kcal/mol) with an unfavorable enthalpy change (ΔH =
2.0 kcal/mol) resulting in a value for ΔG of -7.1 kcal/mol.
Rp2d binding is an entropically driven intercalative process which was previously
demonstrated (16). The Ka values of 1.4 x 106 M-1 and 8 x 104 M-1 for this racemic
mixture in the studied buffers are in agreement with data previously collected on the
enantiomers, which was Ka = 3.2 x 106 M-1 and 1.7 x 106 M-1 for Δ and Λ isomers
respectively (16). The total stoichiometry is in line with the ~13 molecules that would be
expected to bind through intercalation limited by neighbor exclusion (17-20).
Rp3 enantiomers were previously found to weakly bind DNA with binding
affinities of 4.9 x 104 M-1 and 2.8 x 104 M-1 for the Δ and Λ isomers respectively (21).
This racemic mixture was found to bind to DNA with a binding constant of
approximately 1.3 x 104 M-1. Binding was previously reported to be electrostatic in nature
and not to proceed via a classical intercalative method (21). The enthalpy was previously
found to be small in magnitude and positive in sign yielding an overall entropically
driven binding process (22). Since hydrogen bond acceptors and donors are not included
in the structure, observed enthalpy changes appear to result from van der Waals contacts,
electrostatic interactions, and/or effects related to the solvation of DNA (22). These
observations are consistent with the data reported in this work. Binding of an Rp3
molecule was reported to remove 3-4 base pairs as potential binding sites from the DNA
lattice which is also in agreement with the approximately five molecules that were found
bound to 25bp duplex DNA in this study (21).
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Table 4.1

Thermodynamic data obtained from ITC experiments performed at 298 K
for the interaction between ligands and dsDNA in Na+ BPES buffer

Figure 4.2 shows CD results for the binding of ligand to the target 25 bp duplex
DNA in Tris buffer. The signal for the titrations of MP into DNA demonstrates an
attenuation in molar ellipticity at 274 nm and undergoes a bathochromic shift up to 2:1
binding. This bathochromic shift was previously seen in experiments with P4+ binding to
a 7 base pair hairpin. Additional ligand shifts the peak to its original wavelength and by
8:1 the molar ellipticity retains only a fraction of its original intensity. The MP ligand is
interacting with the DNA in such a way as to disrupt its structure. This disruption is
likely in the form of unwinding as the intercalating moiety inserts itself between base
stacked bases. Figure 4.3A shows MP bound to the minor grove of DNA and the
displacement of the nucleotide bases to accommodate the intercalation taking place.
Elongation of the duplex has occurred to accommodate the intercalation in these
simulations.
Rp2d titrations demonstrate a hypsochromic shift from 275 to 260 nm for the CD
signal. This 260 nm region is characteristic of A-DNA character, in which the minor
groove has been elongated (23). This suggests the major groove is changing as a result of
binding. This binding mode is illustrated in Figure 4.3B, modelled with ligand binding
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directionally from the minor groove of DNA and one ligand molecule lying in the major
groove.
Rp3 titration experiments do not demonstrate attenuation. This is consistent with
a non-intercalative mode of binding. Chaires previously demonstrated that Rp3 binds to
the major/minor groove of DNA (21, 22). This binding mode is shown in Figure 4.3C.
Figure B.1 repeats the CD experiments in BPES buffer and appears very similar to the
experiments in tris buffer.
As shown in Figure 4.4, the ESI mass spectra observed in the presence of the
various ligands differs from that of the original DNA (shown in Figure 4.4A or 4.4C).
Figure 4.4D shows notable m/z peaks at 1598.2, 1833.9, 2131.3, and 2446.3 which
correspond to DNA*MP complexes of 1 or 2 molecules of MP per molecule of 7 bpHP.
Figure 4.4E shows notable m/z peaks at 1386.2, 1547.2, 1732.7, 1939.2, 2063.3, and
2310.3 which correspond to DNA*Rp2d complexes of 1, 2, or 3 molecules of Rp2d per
molecule of 7 bpHP. Notable m/z peaks in Figure 5.4F are 1521.7, 1681.7, 1841.7,
2029.2, 2242.6, and 2455.6 which correspond to DNA*Rp3 complexes of 1, 2 or 3
molecules of Rp3 per molecule of 7 bpHP.
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Figure 4.2

CD spectra for the subsequent titrations of Ru2+ complexes into DNA in
tris buffer.
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Figure 4.3

Minimized models of MP (A), Rp2d (B), and Rp3 (C) interacting with
duplex DNA; calculated by Clinton G. Mikek of the Lewis lab.
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98
Figure 4.4

ESI-MS of free hairpin DNA and hairpin DNA incubated with a slight excess of the indicated ligand. DNA
illustrated in 4B was prepared with DNA shown in 4A, while 4D, 4E, and 4F were prepared with DNA shown in 4C.

4.5

Discussion
Previous reports have indicated that 1,10-phenanthroline and related analogs are

capable of interacting with DNA through an intercalative binding mode. Complexation
of several phenanthroline molecules to a metal center was previously thought to have a
partial intercalative mode as well (16). Chaires was able to demonstrate that
[Ru(phen)3]2+ binding does not proceed through the classical intercalative mode, but
rather through Van der Waals contacts, electrostatic interactions, and/or effects related to
the solvation of DNA (16). Le et al. reported that P4+ was able to interact with DNA with
an affinity one order of magnitude greater than the Rp3 binding, but that the enthalpy
was similar to that reported by Chaires group. Le et al. presented that P4+ was able to
thread through the DNA base pairs by taking advantage of the “breathing” motion of
DNA (14). Interestingly, the kinetics of the reaction appeared to be relatively fast for a
threading mechanism, perhaps due to the dynamic flux of DNA. To further understand
this intercalative binding mode, MP, Rp2d, and Rp3 (ligand size starting at phen and
building towards tatpp) were bound to 25bp duplex to examine the structure function
relationship of the Ru2+ ligands with DNA.
As a starting point, the validity of 25 bp duplex DNA as a good model DNA was
confirmed by comparing the experiments with Rp3 in this work to the literature. For
Rp3 binding to 25 bp DNA, a similar binding affinity with respect to the previous reports
for the forward titration experiment was obtained (21). Additionally the measured
enthalpy agrees with the results for their Rp3 binding (both were positive, difference was
~0.1 kcal/mol) and the entropic contribution were comparable (ΔS= 28.8 vs 26.8 cal/mol)
especially considering the buffer concentrations differed from their system (16).
99

Further building upon the Rp3 scaffold, the binding of Rp2d was examined. Two
distinct binding events were noted. The first higher affinity binding of 1.2 x 106 was
comparable to that reported by Chaires et al. (16). Interestingly this work yielded a
negative enthalpy, whereas their reported enthalpy for the binding of Rp2d was 0.2
kcal/mol vs this work’s -1.1 kcal/mol, but both obtained a favorable entropic contribution
(16). The difference in enthalpy is small and possibly negligible, but could arise from a
number of factors including the difference in buffer conditions or the differences arising
from the use of different techniques (the entirety of the presented thermodynamic
parameters were derived from ITC, whereas Chaires et al. only reported enthalpies from
ITC and used fluorescence data for the binding constants) (16). Recent advances in
microcalorimetry and the fitting models used to model the binding parameters could also
explain this difference. Nevertheless, using these different models with different DNAs,
similar binding affinities were obtained.
Interestingly, a secondary binding event which was not reported by Chaires et al.
was observed. Similar results of a second binding event were seen in more recent ITC
results of Rp2d with (poly[dAdT])2 by Lincoln et al., where they saw two distinct
binding events via ITC but did not present the values of the thermodynamic parameters of
the second binding event (24). This work’s ITC derived first binding site free energy
change value is nearly identical to their reported value, and both determined the first
binding mode to be entropically driven. The second binding mode was characterized by
a more favorable enthalpic contribution, as was also stated by Lincoln et al., with an
almost equal entropic contribution. While we agree with the assignment of the nature of
the primary ligand binding by Lincoln et al., we do not believe the additional mode to
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simply be that of a canted geometrical binding, but rather a side-on interaction with the
backbone of the DNA or a new intercalative association arising from the original
intercalation which caused a widening of the minor groove (25, 26).
Thermodynamically, a normal and canted intercalation should be relatively similar and
instead two separate binding modes with distinctly different enthalpic and entropic
contributions were observed (27). X-ray crystal structures of both ∆ and Λ complexes
with DNA are available and show two different binding modes for the racemic mixture
(28). Additional crystal structures show the structural variance possible in bound DNA at
differing relative humidities (25). It should be noted that this difference could arise from
the different oligonucleotides used in the two studies. Future ITC titrations with full
thermodynamic characterization of both binding events with [poly(dAdT)]2 would be
useful to compare these two systems. We do not believe the difference in the ITC profile
to be the result of a competitive process between these two modes though, as the two are
added simultaneously and the affinities for both processes are two orders of magnitude
different (29).
In order to complete the link between Rp3 and P4+ the interaction of MP with the
model duplex DNA was examined. A slightly higher binding constant, suggesting a
more favorable interaction for MP with duplex DNA than Rp2d with duplex DNA, was
obtained for MP vs Rp2d. This higher association for the intercalated construct likely
arises not only from the favorable π-π interactions of the extended conjugated system but
also due to the release of unfavorable hydrophobic interactions between the ligand and
solvent system (water) upon binding of the ligand to DNA. Molecular dynamics energy
minimization studies show a closer relationship between the MP Ru2+ center and the
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nucleotides than was observed with the modeling of P4+ complexed with the same DNA.
Perhaps the majority of the additional binding energy comes from this ability to more
closely associate with the backbone and have more favorable ionic interactions instead of
two cationic metal centers competing for the interaction and having a less
thermodynamically stable binding product.
CD titration results assisted in the confirmation of these conclusions. Rp3 shows
little to no effect on the structure of the duplex, as there is no large amount of absorbance
shifts observed. Figure 4.3C shows the Rp3 ligand associating with the grooves of DNA.
Creating an extension from the phenanthroline ligand offers an intercalative ability with a
higher affinity. This increased affinity for the bound mode causes structural changes
through steric interactions between the bulky phenanthroline groups and the DNA
backbone as well as deformation caused by the necessary increase in distance between
base pairs to accommodate the intercalation. For the binding of Rp2d to DNA, the minor
groove is likely widened to near A-form type as seen with the emergence of a positive
peak near 260-270 nm, which is indicative of A-form DNA (23, 30). Figure 4.3B shows
Rp2d intercalating into DNA from the minor groove and widening it to accommodate the
phenanthroline groups lying in the grove. A minor groove binding non-intercalative mode
is also demonstrated in the figure. Increasing the width of the minor groove and major
grooves is necessary for relaxation of the torsional strain caused by intercalation (31).
With the case of MP, there is a drastic attenuation in molar ellipticity in the
region of 275 nm in both buffers examined. Titrations of MP in phosphate buffer
demonstrated emergence of a positive peak near 260-270 nm at mole ratios of ligand in
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excess of the 8 expected for a 25 base pair duplex that would be able bind based on the
Rp3 exclusion observation discussed by Chaires et al. (21).
4.6

Conclusion
The reported ITC, ESI-MS, and CD results from the experiments serve to

examine the structure function relationship of these Ru2+ ligands when binding with
DNA. A marked increase in binding affinity for the mononuclear Ru2+ containing
ligands that are able to intercalate versus the mononuclear Rp3 which has been reported
to not bind through classical intercalation was seen. The favorable entropic contributions
likely arise from the displacement of solvent (water) upon ligand binding, as well as the
unwinding of the duplex. ESI-MS data support the “neighbor exclusion principle” and
exclusion based on the size of Rp3 that has been previously reported (14, 21).
MP binds to dsDNA with an affinity 1.5 kcal/mol greater than that of P4+, while
Rp2d binds with an affinity slightly lower than that of P4+, suggesting that a longer
intercalating moiety but not additional groove binding moiety is able to enhance the
binding of these Ru2+ containing DNA binding ligands. Future studies will examine
more substituted ligands as well as the enantiomerically pure samples of Rp2d and MP
in order to distinguish each enantiomers’ contribution to the thermodynamic parameters.
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SUPPLEMENTARY INFORMATION FOR CHAPTER III
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A.1

Complete ITC titration profiles

Figure A.1

Representative ITC titration profile for the titration of apo-TMPyP4 into
hTel22 in 150 mM K+ BPES buffer.
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Figure A.2

Representative ITC titration profile for the titration of Cu-TMPyP4 into
hTel22 in 150 mM K+ BPES buffer.
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Figure A.3

Representative ITC titration profile for the titration of Ni-TMPyP4 into
hTel22 in 150 mM K+ BPES buffer.
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Figure A.4

Representative ITC titration profile for the titration of Co-TMPyP4 into
hTel22 in 150 mM K+ BPES buffer.
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Figure A.5

Representative ITC titration profile for the titration of Zn-TMPyP4 into
hTel22 in 150 mM K+ BPES buffer.
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Figure A.6

Representative titration profile for the dilution of apo-TMPyP4 in 150 mM
K+ BPES buffer. Note the low endothermic heats of dilution seen.
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Figure A.7

Representative titration profile for the dilution of Cu-TMPyP4 in 150 mM
K+ BPES buffer.

Note the linearly decreasing endothermic heats of dilution seen.
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Figure A.8

Representative titration profile for the dilution of Ni-TMPyP4 in 150 mM
K+ BPES buffer. Note the low endothermic heats of dilution seen.
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Figure A.9

Representative titration profile for the dilution of Co-TMPyP4 in 150 mM
K+ BPES buffer. Note the low endothermic heats of dilution seen.
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Figure A.10 Representative titration profile for the dilution of Zn-TMPyP4 in 150 mM
K+ BPES buffer. Note the low endothermic heats of dilution seen
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Figure A.11 Representative ITC titration profile for the titration of apo-TMPyP4 into
hTel22 in 150 mM Na+ BPES buffer.
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Figure A.12 Representative ITC titration profile for the titration of Cu-TMPyP4 into
hTel22 in 150 mM Na+ BPES buffer.
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Figure A.13 Representative ITC titration profile for the titration of Ni-TMPyP4 into
hTel22 in 150 mM Na+ BPES buffer.
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Figure A.14 Representative ITC titration profile for the titration of Co-TMPyP4 into
hTel22 in 150 mM Na+ BPES buffer.
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Figure A.15 Representative ITC titration profile for the titration of Zn-TMPyP4 into
hTel22 and in 150 mM Na+ BPES buffer.

122

Figure A.16 Representative ITC titration profile for the dilution of apo-TMPyP4 in 150
mM Na+ BPES buffer.
Note the low endothermic heats of dilution seen.
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Figure A.17 Representative titration profile for the dilution of Cu-TMPyP4 in 150 mM
Na+ BPES buffer.
Note the linearly decreasing, low endothermic heats of dilution seen.
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Figure A.18 Representative titration profile for the dilution of Ni-TMPyP4 in 150 mM
Na+ BPES buffer.
Note the low exothermic heats of dilution seen.
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Figure A.19 Representative titration profile for the dilution of Zn-TMPyP4 in 150 mM
Na+ BPES buffer.
Note the low heats of dilution seen
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A.2

Titrations at 60 mM supporting electrolyte
In addition to the published work, titrations at 60 mM supporting electrolyte

concentration were performed. Below are those data compared to the published data for
apo-, Cu-, and Zn-TMPyP4

Figure A.20 Representative ITC titration enthalpogram for the titration of apo-TMPyP4
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer.
Changes in Gibbs free energies and enthalpies are given in kcal/mol.
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Figure A.21 Representative ITC titration enthalpogram for the titration of Ni-TMPyP4
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer.
Changes Gibbs free energies and enthalpies are given in kcal/mol.
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Figure A.22 Representative ITC titration enthalpogram for the titration of Cu-TMPyP4
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer
Gibbs free energies and enthalpies are given in kcal/mol.
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A.3

Circular dichroism spectra for titrations

130
Figure A.23 CD spectra for the titration of TMPyP4 into hTel22 in either 60 or 150 mM Na+ or K+ BPES.
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Figure A.24 CD spectra for the titration of Ni-TMPyP4 into hTel22 in either 60 or 150 mM Na+ or K+ BPES.
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Figure A.25 CD spectra for the titration of Cu-TMPyP4 into hTel22 in either 60 or 150 mM Na+ or K+ BPES.
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B.1

ITC final figures

Figure B.1

Representative ITC titration profile for the titration of MP into tris buffer.
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Figure B.2

Representative ITC titration profile for the titration of MP into 25 bp
duplex DNA in tris buffer.
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Figure B.3

Representative ITC titration profile for the titration of Rp2d into tris
buffer.
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Figure B.4

Representative ITC titration profile for the titration of Rp2d into 25 bp
duplex DNA in tris buffer.
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Figure B.5

Representative ITC titration profile for the titration of Rp3 into tris buffer.
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Figure B.6

Representative ITC titration profile for the titration of Rp3 into 25 bp
duplex DNA in tris buffer.

139

Figure B.7

Representative ITC titration profile for the titration of MP into Na+ BPES
buffer.

140

Figure B.8

Representative ITC titration profile for the titration of MP into 25 bp
duplex DNA in Na+ BPES buffer.
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Figure B.9

Representative ITC titration profile for the titration of Rp2d into Na+ BPES
buffer.

142

Figure B.10 Representative ITC titration profile for the titration of Rp2d into 25 bp
duplex DNA in Na+ BPES buffer.
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Figure B.11 Representative ITC titration profile for the titration of Rp3 into Na+ BPES
buffer.
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Figure B.12 Representative ITC titration profile for the titration of RP3 into 25 bp
duplex DNA in Na+ BPES buffer.
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B.2

Circular dichroism spectra for titrations

146
Figure B.13 CD spectra for the titration of MP into duplex DNA in Na+ BPES buffer.
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Figure B.14 CD spectra for the titration of Rp2d into duplex DNA in Na+BPES buffer.
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Figure B.15

CD spectra for the titration of Rp3 into duplex DNA in Na+BPES buffer.

Table B.1

Thermodynamic Data obtained from ITC Experiments performed at 298 K
for the interactions between ligands and 25bp duplex in tris buffer.
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